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ABSTRACT 
 
 
Chronic inflammation is causally associated to many types of tumor, and has been 
recently acknowledged as a cancer hallmark. Nevertheless, whether inflammation has 
an intrinsic mutagenic potential is still not directly proven or understood from a 
mechanistic point of view. Furthermore, it is as yet unclear whether inflammation 
could induce epigenetic modifications, and if these changes are relevant to tumor 
generation. 
Therefore, the aim of this work was to assess inflammation-derived genomic and 
epigenomic modifications at multiple stages of tumorigenesis in Mdr2-knockout mice, 
a model of purely inflammatory hepatocellular carcinoma (HCC). 
By ChIPseq profiling of H3K27Ac mark we reported the establishment of an 
inflammatory program specifically in hepatocytes starting from the pre-malignant, 
chronic inflammatory step. This inflammatory signature is retained up to the more 
advanced HCC stage, and is accompanied by the activation of members of the AP1 
transcription factor family. 
In parallel, by whole exome sequencing, we observed a high frequency of copy 
number amplifications and a very low number of point mutations in HCC nodules. 
Copy number variations occurrence was directly correlated to the grade of malignancy 
in each lesion. The JNK pathway was shown to be pervasively targeted by gene 
amplification, and to be involved in the adenoma-to-carcinoma transition. A 
comparable genetic landscape has been observed in a human liver cancer with similar 
etiology. 
In conclusion, this study shows that in a model of inflammation-driven cancer an 
epigenetic inflammatory signature is early acquired and maintained throughout 
disease progression. On the contrary, genetic alterations appear only at later stages 
and mainly target the JNK pathway. Future dataset integration will help clarifying 
chronological relationship and possible mutual interplay between mutations and 
epigenetic changes. 
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INTRODUCTION 
 
 
1. Genetic and epigenetic factors in cancer	  
1.1  Genetic alterations in cancer 
The intuition of cancer as a “disease of the genome” came from Theodor Boveri at the 
beginning of the twentieth century [1].  Eighty years later, a proof of principle for this 
concept was eventually provided by the earliest reports of mutated cancer-causing 
genes [2, 3]. Classification of such genes as oncogenes and tumor suppressors 
became soon established [4]. The variety of genetic alterations occurring (such as 
point mutations, copy number variations, chromosomal rearrangements) began to be 
described, and to shed light on the underlying genomic complexity of cancer, on the 
multiplicity of tumor-causing genes and their variability across and within cancer types 
[5, 6]. 
Nevertheless, the field of “cancer genomics”, namely the systematic and genome scale 
analysis of cancer genomes to identify recurrent alterations for specific tumor types, 
started off only recently. After a pilot project, the Cancer Genome Atlas was launched 
by the National Cancer Institute in US in 2009, in parallel to the establishment of an 
International Genome Consortium [7]. The challenge of creating a compendium of 
genomic alterations for each given tumor type was made easier by the advent of next-
generation sequencing (NGS) approaches based on massively parallel sequencing [8]. 
From the first whole cancer genome study performed by NGS [9], where a single 
sequencing run could analyze around 1 billion bases, the technology evolved to the 
current throughput of >600 gigabases per run. As the costs of NGS progressively 
dropped, sequencing of large number of samples became more affordable, giving rise 
to a large diffusion of large scale studies carried out on primary patients samples. 
An optimization of the NGS technology for the analysis of cancer genomes was 
dependent on the design of hybridization-based selection techniques (collectively 
referred to as “target enrichment”) to sequence sub-portions of genome, specifically 
the whole complement of coding and non-coding exons (exome) [10]. Moreover, the 
development of robust bioinformatic approaches allowed taking advantage of NGS-
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based platforms for the analysis of a panel of different genetic alterations (point 
mutations, copy number variations), or functional outcomes (transcriptomic 
measurements, epigenetic modifications profiling, chromatin structure analysis).   
The explosion of sequencing data originated from NGS diffusion allowed providing a 
number of unprecedented insights on the variegated mutational spectra across 
different tumor types. The mutation frequency is highly variable, ranging from 0.5/Mb 
for acute myeloid leukemia to around 90/Mb in solid tumors such as melanoma [11, 
12]. New evidences of the high dependence of mutational patterns on etiological 
factors (being them external, such as smoke or UV exposure, or internal, as DNA 
repair mechanism defects) were presented [13, 14]. Furthermore, new mutational 
processes have been uncovered. For example, a new regional hypermutation 
mechanism characterized by multiple base mutations occurring in cis close to 
rearrangement breakpoints, initially identified in breast cancer and soon after 
recognized also in many other tumor types, has been termed “kataegis” [15, 16]. This 
phenomenon is thought to depend on the activation-induced deaminase (AID) and 
apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) families of 
proteins. More extensive damage comes from other new mutational mechanisms, 
consisting of catastrophic events (defined as one-step massive genomic alterations 
with respect to step-wise multiple mutations) resulting in high degrees of 
rearrangements. “Chromothripsis”, or chromosomal shattering, occurs in ~2-3% of 
cancers and usually involves massive rearrangements of one or two chromosomes, 
with large portions of chromosomes fluctuating between two distinct copy number 
states [17]. This appears to result from errors in mitotic chromosomal segregation, 
which would cause the confinement of single chromosomes into “micronuclei”. 
Micronuclear chromosomes would be subject to premature chromosome condensation 
and consequent breaks in the incompletely replicated DNA (chromosome 
pulverization): a few chromosomes might survive this process via aberrant non-
homologous end joining, giving rise to densely rearranged elements [18].  
Besides shedding light on newly identified mutational processes, high throughput 
cancer sequencing studies strengthened our knowledge on mechanisms already 
established as characteristic of tumoral conditions. Aneuploidy (an abnormal number 
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of chromosomes), a typical feature of cancerous cells, was systematically assessed on 
large-scale studies, along with focal copy number variations of variable entity. In 
particular, it has been estimated that large-scale events affect on average ~25% of a 
cancer genome, while 10% is target of focal gains/losses involving a median of 6-7 
genes [19]. 
The huge amount of information regarding mutations and copy number alterations has 
been integrated in the search for conserved cancer signatures. The analysis of a 
catalogue of somatic mutations in >7,000 samples across the spectrum of human 
cancers yielded 21 distinct mutational signatures, some of which are conserved among 
different tumors while others are specific to a given type [16]. Although most cancer 
classes present at least two signatures, some cancers (such as liver, uterus and 
stomach) can display up to six signatures, suggesting a higher degree of complexity in 
their mutational processes [16]. A recent work on ~3,000 samples (from 12 different 
cancer types) retrieved 30 tissue-independent tumor subclasses, based on oncogenic 
signatures [20]. Interestingly, the same study observed that tumors, independently of 
their origin, present an inverse correlation between the number of somatic mutations 
and the number of recurrent copy number variations. Accordingly, tumors have been 
reported to subdivide into two main classes, one principally bearing somatic mutations 
and one predominantly characterized by copy number alterations [20].  
Such efforts towards the integration of large amounts of genomic data will help in 
understanding tumor biology in terms of signatures systematically derived from 
functional alterations, and will possibly catalyze the elaboration of personalized cancer 
therapies. 
 
1.2  Cancer epigenetics 
Beside proposing the genetic origin of cancer, Boveri was probably also the first to 
observe an epigenetic aberration in cancer, by describing the abnormal appearance of 
chromatin in tumor cells as early as in 1929 [1]. This occurred more than a decade 
before the term “epigenetics” had been used for the first time by Conrad Waddington 
to define “the interactions of genes with their environment which bring the phenotype 
 18 
into being” [21]. Epigenetics was originally defined as the study of changes in gene 
expression caused by mechanisms different from DNA sequence modifications, such as 
changes in DNA methylation and chromatin remodeling. The concept became further 
extended after the recent spread of genomic studies, and the field of “epigenomics”, 
intended as the study of the  “effects of chromatin structure, including the higher 
order of chromatin folding and attachment to the nuclear matrix, packaging of DNA 
around nucleosomes, covalent modifications of histone tails (acetylation, methylation, 
phosphorylation, ubiquitination), and DNA methylation” [22]. 
The cellular transformation process needs the acquired malignant features to be 
permanently encoded in order to allow their transmission and accumulation along the 
clonal expansion. Genetic mutations represent the most obvious mechanism to convey 
stable phenotypic changes. For this reason, cancer has been considered for a long 
time from a gene-centric viewpoint, with DNA mutations being assigned a primary role 
in generating its hallmark properties. This diverted the attention from the possible 
importance of epigenomic dysregulations, initially regarded as “surrogates” of genetic 
changes [23], and from their capability of being flexible, but still inheritable through 
multiple cell divisions. 
The first demonstration of a connection between cancer and epigenetic processes 
came in 1983 from Feinberg and Vogelstein, who first described the hypomethylation 
of colorectal tumor cells DNA [24]. This observation was soon extended to a variety of 
tumors and pre-malignant lesions [25], DNA hypomethylation becoming an ubiquitous 
feature of tumor cells. Classical observation include a global hypomethylation of 
cancer cells DNA, occurring during early tumorigenic steps and thought to favor 
genomic instability [26], and focal hypermethylation at particular CG dinucleotide-rich 
regions called CpG islands (CGIs) [27]. CGIs have been found enriched in more than 
70% of human promoters, and for this reason CGI hypermethylation is associated to 
transcription silencing [28]. More recently, a number of reports showed that most 
methylation differences between tissues (including normal vs. cancerous tissue), as 
well as between pluripotent and differentiated cells, occur outside of CGIs but within 
2kb from their boundaries, in regions that were named CGI shores [29, 30]. 
Furthermore, cancer has been associated to a loss of sharply defined boundaries 
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between low- and high-methylated areas (CGI and CGI shores). In particular, 
methylation hypervariability in CGI shores, when found in phenotypically normal 
tissue, is predictive of tumorigenesis onset [31]. 
When considering the effects of a global (rather than a local) loss in DNA methylation, 
genomic instability has long been thought to derive from re-mobilization of normally 
silent transposon elements [32]. Also loss of imprinting (LOI) events, by relieving 
repression on entire chromosomes or part of chromosomes, could lead to 
overexpression of oncogenes and silencing of tumor suppressors [33]. Notably, these 
phenomena have also been attributed to loss of repressive histone marks such as tri-
methylation of lysine 9 on histone H3 (H3K9me3), tri-methylation of lysine 20 on 
histone H4 (H4K20me3) and tri-methylation of lysine 27 on histone H3 (H3K27me3) 
[34-36]. 
Indeed, it is now clear that a crosstalk between DNA methylation and histone 
modifications exists (mediated at least in part by interactions between histone- and 
DNA-methyltransferases), suggesting an interdependence of the two types of 
epigenetic mechanisms [37]. For example, CGI promoter hypermethylation, 
associated to gene repression, often coincides with loss of histone marks typical of 
active genes (including H3 and H4 acetylation and H3 lysine trimethylation) [37]. A 
decade ago, Vogelstein and colleagues reported that tumor suppressor gene silencing 
appears to be induced by histone modifications prior to changes in DNA methylation 
[38]. The hypothesis of tumor suppressor silencing being primarily correlated with 
histone modifications rather than DNA methylation has been further supported by an 
increasing number of studies [37, 39-41]. This would be in agreement with reports 
showing that CGI hypermethylation in cancer occurs at genes that have already been 
silenced in non-tumoral tissue, and that it normally follows chromatin modification 
during development [40, 42, 43].  
Surprisingly, out of >60 histone residues for which modifications have been identified, 
only a few have been associated to cancer to date, along with alterations in histone-
modifying enzymes expression or activity [44]. The first histone mark deregulation 
found in cancer has been the combined loss of global acetylation of histone H4 at 
lysine 16 (H4K16Ac) and H4K20me3, occurring (along with DNA hypomethylation) at 
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repetitive sequences, and correlating with tumor progression [45]. H4K16Ac is 
thought to influence histone-chromatin interactions and to regulate chromatin folding, 
while H4K20me3 is usually linked to heterochromatic regions [46, 47].  
Nevertheless, the most frequently altered modifications in tumors have been reported 
to be di- and tri-methylation of histone H3 at lysine 4 (H3K4me2/me3), normally 
positioned near transcription start sites and associated to transcriptional activation, 
and found to be decreased in a range of cancer types [48-51]. This finding is 
accompanied by the observation of an aberrant expression or activity of several 
enzymes controlling H3K4me2/me3 levels, such as the histone demethylases (HDMs) 
LSD1 and JARID1 and the histone methyltransferases (HMTs) of the MLL family (in the 
latter case due to protein fusion) [52-55]. Another mark commonly altered in cancer is 
H3K27me3, linked to repressive chromatin domains and sustained by the Polycomb 
repressive complex 2 (PRC2). In this case, both evidence of increase and decrease of 
activity of H3K27me3-controlling enzymes (such as the EZH2 component of PRC2, and 
the HDMs JMJD3 and UTX) and of levels of H3K27me3 have been reported, suggesting 
the importance of a proper equilibrium for this modification in the maintainance of 
normal cell growth [56-60]. The same bivalency has been described for H3K9me3, a 
typical mark of heterochromatin and transcriptional repression [61-64].  
As in the case of DNA methylation, also disruption of normal histone modification 
patterns may have impacts on genome instability, and cause relevant changes to gene 
expression and higher order chromatin interactions. The balance between euchromatic 
and heterochromatic histone marks appear to be critical to this respect, and cancer 
therapies focused in repairing the loss of this equilibrium (such as inhibitors of HMTs, 
histone acetyltransferases or deacetylases) are being increasingly considered [65], 
though the precise rational bases for some of these therapies is still unclear. 
 
1.2.1 The epigenetic cancer progenitor model 
A wealth of epidemiological evidences has associated pre- and postnatal 
environmental factors to risk of adult development of several chronic diseases, 
including cardiovascular diseases, obesity, diabetes and cancer [66, 67]. Furthermore, 
cases of environmental prenatal and early postnatal environmental factors (such as 
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nutrition [68], xenobiotics [69], and low-dose radiation [70]) linked to aberrant 
epigenetic programming and higher disease risk have been frequently reported in 
literature. On the basis of these observations, Jirtle and Skinner proposed the  
“developmental origins of adult-onset disease” theory to account for the relationship 
between early environmental inputs and epigenetic alterations [71]. According to this 
model, the early adaptation of an organism to environmental influences (referred to as 
“developmental plasticity”) can lead to a higher risk of chronic disease development in 
cases where the perceived environment will differ from the one experienced 
subsequently in adulthood. 
In relation to tumor biology, the hypothesis of an “epigenetic progenitor” origin has 
been proposed [23], stemming from the observation of the reversibility of cancer 
phenotype in given conditions [72, 73]. Indeed, several studies demonstrated that 
tumor cells could revert to normal phenotypes upon exposure to specific 
environmental cues, a phenomenon that would be hardly explained in the context of 
permanent, genetic mutations [74, 75]. According to the epigenetic progenitor model, 
the first step of tumorigenesis would involve the epigenetic disruption of the 
progenitor cell, which would favor the occurrence of an initiating mutation and the 
acquisition of an enhanced genetic and epigenetic plasticity. In this light, reversible 
(epigenetic) changes could lead to irreversible (genetic) modifications, possibly by 
uncovering detrimental genetic variants (including transmissible ones) that are 
normally kept silenced by epigenetic mechanisms [23]. More recently, these concepts 
have been further extended [41], by proposing cancer as the consequence of an 
“epigenetic dysregulation”. In this condition, the epigenome is endowed with a higher 
degree of plasticity, explaining the high phenotypic variability occurring among 
individual lesions, and favoring the natural selection of altered cells on a much shorter 
timescale than the one allowed by mutation variability [41]. 
The model of the “epigenetic progenitor” is gradually receiving confirmation from 
emerging evidences of an early involvement of epigenetic aberrations in 
tumorigenesis. In colorectal cancer, LOI of the insulin-like growth factor 2 (IGF2) 
mitogen is detected in both normal and neoplastic tissue, and induction of Igf2 LOI 
increases tumor frequency [76]. Epigenetic alterations are identified at the earliest 
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steps of epithelial carcinogenesis in Barrett’s oesophagus and in cervical cancer, 
largely before invasive malignancy onset [31, 77]. More recently, a large study found 
alterations in DNA methylation in the normal tissue of patients affected by different 
cancer types, with the number of alterations being directly correlated with age, 
providing a mechanism for the age-dependency of cancer frequency [78]. 
 
1.3  The interplay between genetic and epigenetic factors in cancer 
The first case of genetic disruption of an epigenetic regulator in the context of cancer 
was identified in 1998 in malignant rhabdoid tumors caused by the mutation of the 
chromatin remodeler SMARCB1/SNF5 [79]. In the following years and especially after 
the diffusion of high-throughput sequencing studies, many other epigenetic 
modulators have been found mutated in cancer. Genes involved in epigenetic 
mechanisms represent half of the most significantly mutated genes in 
medulloblastoma [80], and are genetically altered in half of bladder cancers [81] and 
hepatocellular carcinomas [14]. The group of epigenetic modifiers most frequently 
targeted by mutation in common solid tumors is the chromatin remodeling class 
(including ARID1A, mutated in more than ten cancer types), whose inactivation causes 
an increase in euchromatic regions and in consequent gene activation [41, 82]. 
Nevertheless, most of the mutations on epigenetic modifiers isolated so far in solid 
tumors belong to either pediatric lesions (as in the case of childhood glioblastoma, 
having a 35.6% frequency of mutations on the histone variant H3F3A, in contrast to 
the 3.4% frequency in adult glioblastomas [83]), or rare, more aggressive variants of 
adult cancers (such as the rare pancreas neuroendocrine cancer, showing a 44% 
mutation frequency on the HMT multiple endocrine neoplasia 1 (MEN1), differently 
from the common pancreatic adenocarcinoma which only associates to an 8% 
frequency of mutation of the histone acetyltransferase p300 [84]). On the contrary, 
genetic disruption of epigenetic players is a frequent event in hematological cancers, 
for example in acute myeloid leukemia and lymphoma [85-87]. 
These observations seem to indicate that, in common solid tumors, epigenetic 
abnormalities are a more frequent tumorigenic mechanism than genetic mutations in 
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epigenetic regulators. The overrepresentation of epigenetic-associated mutations in 
highly aggressive and rare types of lesions further suggests genetic derangement of 
epigenetic machineries to have a particularly heavy impact on cellular activities [41]. 
Epigenetic mechanisms, in turn, can play a fundamental role in the occurrence of 
malignant genetic modifications, to the point of influencing a tumor’s mutation rate. 
Several examples of such condition have been reported in literature [88-95]. 
Apart for relieving the repression of transposon sequences in the genome, DNA 
hypomethylation has been associated to higher frequencies of structural mutability, 
and hypomethylated regions have been found enriched in DNA breakpoints leading to 
copy number variations [88-90]. 
DNA methylation has been found to have a protective effect against DNA double 
strand breaks induced by guanine quadruplexes (G4s), four-stranded structures 
deriving from folding of G-rich sequences (G3N1–7G3N1–7G3N1–7G3). Hypomethylated 
regions frequently include DNA breakpoints, and these are often associated to an 
enrichment in G4s [96]. 
DNA methylation also has an impact on methylation-dependent mutations deriving 
from spontaneous hydrolytic deamination. In contrast to methyl-cytosine deamination, 
which yields a thymine, unmethylated cytosines produce uracils (easily recognized as 
abnormal bases in DNA, and therefore repaired). In highly proliferative tissues, 
deamination of methyl-cytosines in parent strands just before DNA replication (when 
the two DNA strands are detatched) prevents recognition of the lesion and give rise to 
a full C:T substitution. Consequently, the rate of C:T transitions on CpG dinucleotides, 
which are frequently methylated, is ~10 times higher than any other single nucleotide 
variant (SNV) in human genome [91], and 25% of all mutations on TP53 in cancer 
have been attributed to this epigenetic modification [92].  
Chromatin modifications also correlate with mutation rates. High 3K9me3 levels, 
typical of in large repressive domains, are associated to >40% of SNVs in human 
cancers [93], although at least partially due to a lower evolutionary constraint proper 
of heterochromatin [91]. Common fragile sites (CFS), large unstable genomic regions 
sensitive to replication perturbations and variations in copy number, have been found 
to be hypoacetylated [94]. Finally, genome instability can also originate from 
 24 
epigenetic silencing of components of the DNA repair machineries, such as MLH1, 
MGMT, BRCA1, WRN, FANCF, and CHFR [95]. 
Clearly, the genome and epigenome impact on each other in a variety of ways, 
providing complementary mechanisms to reach comparable effects in cancer. 
Several reports described that mutational inactivation and epigenetic silencing of the 
same gene are two mutually exclusive phenomena, in analogy to the occurrence of 
two mutations on the same pathway. Thus VHL, a key tumor suppressor for clear cell 
renal carcinoma, was found mutated in 60% of tumors and silenced by 
hypermethylation in another ~20% [97], and mutation and epigenetic repression are 
mutually exclusive also in the case of E-cadherin in the lobular and ductal forms of 
breast cancer, BRCA1 in ovarian cancer, and CDKN2A in squamous cell lung cancer 
[98-100]. 
Nevertheless, genomic and epigenomic changes can act cooperatively, as in the case 
of the CpG island methylator phenotype (CIMP) and BRAF mutation in colon cancer, 
where CIMP, consisting in high frequencies of DNA hypermethylation on a specific set 
of CGIs, generates a favorable context for BRAF mutation at the early precursor stage 
[14, 101]. 
Altogether, these evidences point to a strong correlation between areas of genetic 
aberration and epigenetic derangement, implying a collaborative effort of mutations 
and epigenetic modifications along the tumorigenic process. 
 
2. Inflammation 
Inflammation is an immediate adaptive attempt to restore tissue homeostasis upon 
noxious insults, including pathogenic infection and physical injury. Acute inflammation 
represents an immediate and short-term type of response, whereby leukocytes 
infiltrate the affected site, remove the triggering stimulus and repair the damaged 
tissue. This well-characterized, physiological response might become pathological if 
not properly terminated. Indeed, chronic inflammation is a persistent, maladaptive 
response composed of active inflammation, tissue destruction and concurrent repair. 
This condition is much less understood, and nevertheless lies at the basis of a number 
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of chronic human disorders, such as allergy, atherosclerosis, autoimmune diseases, 
and cancer. 
 
2.1  Inflammation is a cancer hallmark  
Chronic inflammation has been causally associated to cancer as early as in the 19th 
century by Rudolf Virchow, upon observation of the presence of leukocytes within 
tumors. In time this association received growing support from the literature, to the 
point that tumors have been defined as “wounds that do not heal” [102]. A plethora of 
epidemiological evidences linked chronic inflammation to different forms of cancer. Up 
to 20% of tumors are correlated to microbial infections (for example, chronic viral 
hepatitis and hepatocellular carcinoma, H. pilori and gastric cancer, HPV and cervical 
cancer), 35% can be ascribed to nutrition factors (20% being associated to obesity, 
now acknowledged to be consistently linked to inflammation [103]), 30% can be 
related to inhaled chemicals triggering inflammation (such as smoke, asbestos and 
silica), and many others to autoimmune disorders (as for the case of inflammatory 
bowel disease and colorectal cancer) [104, 105]. Furthermore, inflammatory 
components (cells, cytokines and chemokines) infiltrate most tumor lesions, including 
those not directly caused by an underlying inflammatory condition [106]. Anti-
inflammatory drugs have been reported to prevent tumor onset or delay tumor 
progression in specific cases, notably colon cancer [107]. 
Many interesting insights have been uncovered on the molecular events linking chronic 
inflammation to tumor formation and progression. The emerging picture suggests a 
feed-forward loop where activated innate immune cells stimulate tumor growth and 
progression via secretion of cytokines and pro-inflammatory mediators, and cancer 
cells produce soluble mediators that recruit and activate inflammatory cells, thus 
further fostering tumor progression [108]. 
Furthermore, pro-tumoral inflammation and anti-tumoral immunity coexist at all the 
different steps of the tumorigenic process, and environmental and microenvironmental 
cues control the balance between them [109]. The composition of the cytokine and 
chemokine pool secreted in the inflammatory milieu is particularly important in 
governing this delicate equilibrium [109]. By activating a variety of downstream 
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effectors, including NFκB (nuclear factor kappa-light-chain-enhancer of activated B 
cells), AP1 (activating protein 1), STAT (signal transducer and activator of 
transcription) and SMAD (mothers against decapentaplegic homolog) family 
transcription factors, cytokines can shift this balance to either promote anti-tumoral 
immunity (interleukin (IL) 12, IL1α, interferon (IFN) γ, tumor growth factor (TGF) β), 
or stimulate cancer progression (tumor necrosis factor (TNF) α, IL6, IL1β), although 
clear-cut separation between pro- and anti-tumoral players is not always possible 
(Figure 1). The bioactive molecules that typically compose an inflammatory 
microenvironment promote tumorigenesis at multiple levels, with growth factors 
supporting mitogenic signaling, survival factors inhibiting apoptosis, angiogenic factors 
stimulating neovascularization, enzymes that can remodel the extracellular matrix 
helping invasiveness and metastasis [110, 111]. Indeed, the idea that cancer biology 
could not be exhaustively comprehended considering cancer cells only, but needs to 
entail also the tumor microenvironment, allowed for inflammation to be acknowledged 
as one of the cancer hallmarks itself [112]. 
 
 
Figure 1  
Major signaling pathways and downstream responses of inflammation-related cytokines in 
cancer. DR4 = death receptor 4, FADD = Fas-associated death domain, gp130 = glycoprotein 
130, TRAIL = TNF-related apoptosis-inducing ligand, TRADD = TNF receptor–associated death 
domain protein, TRAF2 = TNF receptor–associated factor 2, TYK2 = tyrosine kinase 2. Adapted 
from [109]. 
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2.2  Inflammation and the acquisition of genetic changes in cancer  
Inflammation is frequently observed at the earliest steps of a tumorigenic process, 
and its ability to foster progression of an early lesion into a frank tumor is out of 
discussion. Nevertheless, a precise assessment of the impact of an inflammatory 
response on tumor onset is challenging. This is partly due to the lack of proper in vivo 
models enabling a clear evaluation of possible effects on the earliest cancerous stages. 
Furthermore, our current knowledge mostly relies on observations performed starting 
from a detectable tumor load, when probably escape of immunitary surveillance had 
already taken place. 
Several lines of evidence suggest that inflammation is associated to genome 
destabilization. In a rodent model of bowel inflammation deriving from ablation of the 
anti-inflammatory IL10 cytokine, mutation frequencies in the colon were increased by 
4-5 fold [113]. A higher mutation rate has been observed also for inflamed tissues in 
non-tumoral conditions. In a comparison of human tumors and matched healthy 
tissues, the only exception to the much lower mutation frequency scored by normal 
tissues was an inflamed sample, reaching a rate of 4*10−8 mutations/bp (in contrast 
to <1*10−8 mutations/bp for the non-inflamed samples) [114]. Microsatellite 
instability and high frequencies of p53 mutations have been reported in the tissues of 
non-oncologic patients affected by pancreatitis, ulcerative colitis, rheumatoid arthritis 
and atherosclerosis [115-117]. Copy number variations, LOI and mutations on tumor 
suppressor genes have been also documented in tumor-related stroma, although 
these findings are controversial [118-120]. 
Yet, in spite of these correlative data, a clear proof of a direct mutagenic potential of 
inflammation is still missing. Activated macrophages and neutrophils produce ROS and 
RNS that can cause DNA damage, and that are therefore obvious inflammation-
associated candidates to explain genomic instability. Nevertheless, whether ROS and 
RNS released by inflammatory cells are stable enough to react with DNA packed into 
chromatin after having diffused through the extracellular matrix, penetrated a cell, 
crossed its cytoplasm, and entered the nucleus, is still unclear. A possibility is that 
immunity cells could induce ROS accumulation in the surrounding epithelial cells via 
TNFα secretion. However, the activation of scavenging mechanisms during chronic 
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inflammation should dampen the ability of ROS and RNS to cause damage to cellular 
structures. 
Besides causing the production of genotoxic compounds, inflammation could also drive 
mutagenesis by impacting on DNA repair systems. Members of the mismatch repair 
machinery are downregulated by ROS and RNS, which is associated to an increase in 
microsatellite instability [121], and few evidences suggest an impact also on the base 
excision and the nucleotide excision patways [121]. 
Another mechanism that could provide a rationale for an inflammatory mutagenic 
property is linked to AID, a DNA/RNA editing enzyme physiologically responsible for 
the immunoglobulin gene class hypermutation in B cells. AID has been found 
overexpressed in a number of tumors and surrounding inflamed tissues, such as 
chronic gastritis and gastric cancer, inflamed colon and colitis-associated cancer, 
inflamed liver and hepatocellular carcinoma [122-124]. AID expression is dependent 
on several cytokines, including TNFα, IL1β and TGFβ, and has been described to 
induce aberrant double strand breaks (and consequently, mutations and 
translocations) on Myc and BCL6 [125, 126]. 
Finally, an intriguing possibility is that inflammation could lead to the production of 
cytokines and growth factors that would impart stem cell-like properties to tumor 
progenitors and foster the expansion of the stem cell pool. In this regard, a recent 
work has shown that ROS, apart from acting as damaging agents, can also act as 
signaling molecules and induce NFκB-dependent initiation of colon cancer by intestinal 
stem cells at the crypts base [127]. 
However, final proof that any of these inflammation-driven phenomena actually make 
a crucial contribution to cancer initiation is still missing, and further studies will be 
necessary to unequivocally determine which mechanism is at the basis of 
inflammation mutagenicity. 
 
2.3  Inflammation and epigenetics 
Since aberrant epigenomic changes have been causally associated to oncogenesis, an 
impact of chronic inflammation on epigenetic mechanisms has been hypothesized as a 
causing event for inflammation-driven tumor initiation. This connection would also 
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provide a further explanation to how environmental cues could trigger a tumorigenic 
process, as postulated by the epigenetic progenitor model [23]. In particular, the 
achievement of a more dynamic epigenetic profile (that would eventually allow for the 
acquisition of a malignant epigenetic pattern) has been proposed to derive from the 
reiterated rearrangement of the epigenetic landscape occurring in an inflammatory 
context [41]. 
Both inflammation and alterations in epigenetic control are early features of a 
malignant lesion, and are often reported to take place at pre-neoplastic stages. Yet, 
whether they act concomitantly to promote cancer initiation, or if one of the two 
processes is secondary and dependent on the former, it is still not completely clear. 
Nevertheless, evidences in support of epigenetic consequences of an inflammatory 
condition are now starting to accumulate. 
ROS and RNS have been found implicated also in modulating epigenetic regulators. 
For example, oxidative stress has been described to cause the activation of silenced 
genes by inactivation of histone deacetylases (HDACs) [128]. It can also favor the 
oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, which is not recognized by 
the DNA methyltransferase 1 (DNMT1) and therefore leads to methylation loss after 
mitosis [129]. On the contrary, halogenated byproducts of inflammatory responses 
could result in a methylation gain. Specifically, HOCl (produced by neutrophils 
myeloperoxidase) and HOBr (deriving from eosinophils peroxidases) interact with 
unmethylated cytosines yielding 5-chlorocytosines and 5-bromocytosines, 
respectively. These two halogenated cytosines mimick the 5-methylcytosine and 
cannot be distinguished by DNMT1, which therefore inserts a stable methylation at the 
modified site [129]. 
DNA methylation levels have been shown to undergo alterations during inflammation 
also independently of oxidative stress phenomena. A global hypermethylation has 
been observed in non-cancerous tissues of oncologic patients with respect to healthy 
individuals [130], and during systemic inflammation in patients affected by chronic 
kidney disease or atherosclerosis [131, 132]. Furthermore, several reports show IL6 
to modulate DNA methylation in erythroleukemia, cholangiocarcinoma and oral cancer 
[133-135]. 
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Hahn and colleagues found ~60% of cancer-associated DNA methylation changes to 
be present already in pre-malignant, inflamed tissue, and that the degree of 
inflammation-specific DNA methylation retained in tumor is much more significant 
than the age-dependent DNA methylation [136]. The same study showed that 70% of 
the genes associated with inflammation-dependent DNA methylation are Polycomb 
targets, and that acquisition of DNA methylation at CGI seems to be directed by 
Polycomb and to correlate frequently with a concomitant loss in H3K27me3 [136]. In 
addition, Jmjd3, an H3K27me3-specific HDM, was demonstrated to be induced by 
inflammatory stimuli in macrophages [137]. More recently, induction of colitis in a 
mouse model of colon cancer changed (most often decreased) H3K27me3 levels at 
~3600 regions, with some of these changes being retained along the progression to 
tumor [138]. 
All these data support the hypothesis that chronic inflammation may promote a 
progressive deterioration of epigenetic marks, in turn favoring cancer development. 
Further studies will help to better characterize the interplay and the temporal 
relationship between inflammation and epigenetic derangement. 
 
3. Liver cancer 
The liver is the largest gland in the body, accounting for 2%-5% of body weight. It 
exerts a plethora of essential functions, such as production of endocrine (insulin-like 
growth factors, thrombopoietin, angiotensinogen), exocrine (bile) and plasma protein 
(albumin, apolipoproteins) secretions, storage of glycogen, modulation of cholesterol 
synthesis and transport, drug detoxification and control of metabolism. 
Given its crucial role on the maintenance of physiological homeostasis, liver pathologic 
conditions (including fibrosis, cirrhosis, hepatitis, cholestasis, and hepatocarcinoma) 
are generally associated to high morbidity and mortality rates. In particular, liver 
cancer is the 6th commonest malignant lesion and the 3rd cause of cancer-related 
death worldwide [139], hepatocellular carcinoma (HCC) being the principal histological 
type. Differently from other carcinomas, an increase in its incidence is observed, with 
~750,000 new cases and ~700,000 deaths reported globally every year. Survival 
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rates did not significantly rise over the last three decades, and the available 
therapeutic approaches are yet currently limited to surgery, percutaneous and 
transarterial interventions, and treatment with sorafenib, a multikinase inhibitor 
blocking the MAPK pathway [140]. 
The lack of targeted molecular therapies is largely due to the complexity and 
heterogeneity of HCC, and the presence in a large fraction of cases of concurrent liver 
disease. Indeed, >80% of HCC lesions originate in a context of liver cirrhosis [141]. 
Other pathological situations commonly associated to HCC include nonalcoholic 
steatohepatitis, nonalcoholic fatty liver disease, autoimmune hepatitis, diabetes 
mellitus, hereditary metabolic liver diseases (e.g. α1-antitripsyn deficiency, 
hemochromatosis, glycogen storage disease type I) and obesity [142-147]. 
Nevertheless, the vast majority of HCCs develop after chronic infection from HBV, HCV 
or HDV or chronic exposure to toxins (e.g. alcohol, aflatoxins) [148]. 
 
3.1 Human HCC has been sequenced 
The complexity of liver cancer mutational repertoire has been underlined in a recent 
study, where it has been associated to the maximum number of mutational signatures 
identified for a cancer class: whereas most tumor types display two possible 
mutational signatures, liver tumor reaches six signatures [16]. Indeed, many genes 
are altered in HCC, but the frequency of individual gene mutations is low, therefore no 
universal genetic modification has been found in HCC. Nevertheless, the application of 
NGS technologies disclosed previously uncharacterized mutation patterns and 
chromosomal alterations, shedding light on the genetic heterogeneity deriving from 
different HCC etiologies. 
A number of recent publications report whole-genome sequencing (WGS) or whole-
exome sequencing (WES) data on HCC [14, 149-155], in patients with either viral 
infection (HCV or HBV) or chronic exposure to alcohol.  
Mutation frequencies stated in these articles are in line with other solid tumors. Up to 
3739 genes have been found mutated in the analyzed patients [155], and several 
genes were recurrently mutated (Tp53, Ctnbb1, Arid1a and 2, Axin1, Mll, Tert), most 
of them being well-known oncogenes [14, 149-155]. 
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The major types of base substitution observed in these samples are T>C/A>G 
transitions and G>T/C>A transversions [14, 150, 152, 154]. Interestingly, G>T/C>A 
transversions are known as a hallmark of aflatoxin B1 mutagenic exposure [156]. 
Furthermore, Guichard and colleagues observed that G>T/C>A substitutions were 
significantly more frequent in lesions stemming in a non-cirrhotic liver [152], and 
Huang et al. reported them to be common in HBV-derived HCCs with portal vein 
thrombosis [154]. On the other hand, T>C/A>G transitions at ApT sites have been 
primarily found in HCV-related HCCs [150]. Additionally, also chronic alcohol 
consumption and occurrence of multiple liver nodules displayed a significant 
association with components of the somatic substitution pattern [14].  
These genomic studies also generally reported a high number of small indels (as many 
as 670 in the work by Totoki and colleagues [150]).  
Frequent copy number variations (CNVs) have been detected [14, 149, 152, 153, 
155], often spanning entire chromosome arms, and with copy number deletions being 
generally predominant over amplifications. Several rearrangements (including gene 
fusions) have been listed, mostly at copy number boundaries [14, 150, 155]. 
Interestingly, Sung et al. noted that CNVs were mostly accumulating at HBV 
integration breakpoints [153], and Fujimoto et al. found HBV to integrate most often 
within or upstream of TERT [14], thereby highlighting the contribution of viral 
integration events as a source of chromosomal instability and as a specific cancer 
signature.  
The top 5 pathways recurrently altered were stated to include, in order of frequency, 
the Wnt/beta-catenin, p53/apoptosis and cell cycle control, chromatin remodeling, 
PI3K/Ras and oxidative and endoplasmic reticulum stress pathways [152]. In 
particular, mutations in ≥1 gene involved in the chromatin-remodeling pathway, 
including ARID1A, ARID1B, ARID2, MLL, MLL3, BAZ2B, BRD8, BPTF, BRE, HIST1H4B 
and SMARCA genes, were found in 24% [152] and 52% [14] of the HCC cohorts taken 
into account. 
CTNNB1 mutations were found to be more frequent in HCV- than in HBV-driven HCCs, 
and to be mutually exclusive with TP53 mutation [151, 152]. Also mutations on the 
gene encoding for ARID2, a subunit of a SWI/SNF chromatin-remodeling complex, 
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were estimated to occur more frequently in HCV-HCCs and to be mutually exclusive 
with mutations on TP53, and it has been reported to be correlated with CTNNB1 
mutations [151]. Nevertheless, Guichard and colleagues observed that mutations on 
ARID1A, another member of the ARID protein superfamily, despite being associated to 
CTNNB1 mutations and mutually exclusive with ARID2 mutations, were more 
frequently detected in alcohol-related HCCs [152]. 
On the contrary, mutations leading to inactivation of IRF2, and consequent disruption 
of TP53 function, were specifically associated to HBV-derived lesions [152]. Moreover, 
a higher degree of CNVs and chromosomal instability has been reported in HBV-
related lesions, HCCs having TP53 mutated and tumors developed in a non-cirrhotic 
background [152]. 
Finally, mutations on AXIN1 and APC genes were observed in HCCs with different 
etiologies. However, mutations on RPS6KA3, a ribosomal protein kinase involved in 
PI3K/Ras signaling, were associated to AXIN1 mutations and found mainly in tumors 
without cirrhosis [152]. 
All together, these findings shed light on the impact of etiology on the mutagenic 
pattern of each individual HCC lesion. Nevertheless, most of the tumors analyzed in 
these studies were originating from an environmental cause, including viral infection 
and exposure to chemicals. Such a pervasive impact of external agents on the 
genomics alterations acquired in HCC has so far prevented a definitive understanding 
of the direct contribution of conditions such as cirrhosis, fibrosis, and, in general, 
chronic inflammation to disease initiation and progression. Therefore, despite the clear 
inflammatory component of the tumorigenic process triggered by these factors, the 
impact of inflammation per se, independently of other associated etiologic elements 
has yet to be investigated. 
 
3.2 Mdr2-KO mice: a model of spontaneous, purely inflammatory 
tumorigenesis 
The multidrug resistance 2 (Mdr2) knockout mouse (FVB.129P2-Abcb4tm1Bor) 
represents a well-characterized model of spontaneous hepatocarcinogenesis in the 
context of chronic inflammation. Mdr2 (or ATP-binding cassette B4, Abcb4), ortholog 
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of the human Mdr3, encodes for the P-glycoprotein responsible for flipping the 
phosphatidylcholine (PC) phospholipid from the inner to the outer leaflet of the 
hepatocytes canalicular membrane (Figure 2) [157, 158]. It is expressed at low 
levels also in spleen, skeletal muscle, adrenal gland, tonsil and heart, but no 
morphologic or histologic abnormality has been scored in districts other than liver in 
KO mice [157]. 
Under physiologic conditions, biliary PC is transported into bile ducts via MDR2 and 
subsequently forms mixed phospholipid-cholesterol-bile acid micelles, thus protecting 
cholangiocytes from injury caused by monomeric bile acid. The lack of biliary PC in 
Mdr2-KO mice therefore results in persistent biliary epithelium damage, ultimately 
leading to leaky bile ducts with regurgitation of bile acid into portal interstitium and 
consequent inflammatory response. Furthermore, the stability of mixed micelles 
depends on a proper proportion of phospholipids and bile salts, required to maintain 
cholesterol solubility. Destabilization of micelles due to absence of PC would favor 
crystallization of cholesterol and bile lithogenicity, leading to obstruction of bile 
canaliculi and consequent ductural proliferation [159]. 
The pro-inflammatory microenvironment originating in the context of chronic portal 
inflammation impacts on the periportal hepatocytes causing various degrees of injury 
and apoptosis, with subsequent regenerative hyperplasia. Accelerated DNA replication 
is per se error prone and facilitates the occurrence of further pro-tumorigenic 
alterations. On the other hand, pro-inflammatory mediators (particularly TNFα, CCR5 
and NF-κB) derived from the persistent portal inflammation also play a pivotal role 
during the malignant transformation of proliferating hepatocytes and consequent 
tumor progression [158, 160, 161]. 
Similarly to human hepatocellular carcinoma, tumor development in Mdr2-KO mice 
progresses through defined phases, starting from a chronic inflammatory condition 
that ensues at an early stage (as soon as 8 weeks of age) and is characterized by 
periductular mixed inflammatory infiltrate (rich in CD3+ cells), bile duct proliferation 
and hepatomegaly [160, 162]. When mice are approximately 4 months old they 
present portal tract expansion caused by bile duct hyperplasia, and start to be 
affected by severe architectural and cytologic liver dysplasia. At 10 months, multiple 
 35 
adenomatous lesions appear, which later (between 12 and 16 months) give rise to 
grossly visible nodular carcinomas, with a 100% penetrance in the FVB genetic 
background [160, 162]. Since HCCs develops within adenomas [163], each neoplastic 
nodule offers a screenshot of the adenoma-to-carcinoma transition and displays a 
variable HCC fraction (histopathologically measured as “tumor content”), which tends 
to increase with time.  
The existence of clearly identifiable pathological phases, along with the independence 
from external mutagenic stimuli, makes the Mdr2-KO mice a suitable model for the 
study of the impact of inflammation on genetic and epigenetic variations occurring 
over time during a tumorigenic process.  
 
 
Figure 2 
Function of the murine MDR2 floppase on the hepatocyte apical membrane. Adapted from 
[164]. 
 
3.3 Progressive familial intrahepatic cholestasis (PFIC) 
The term “progressive familial intrahepatic cholestasis” (PFIC) was originally used to 
discriminate cholestatic end stage liver disorders in children that could not be ascribed 
to neonatal or pediatric cholestasis such as biliary atresia, Aagenaes syndrome or 
Alagille syndrome. It now defines a heterogeneous class of rare autosomal recessive 
liver diseases, whose common feature is represented by neonatal hepatic cholestasis 
that progresses to fatal liver failure occurring during childhood or adolescence. 
Although rare, PFIC is associated to 10-15% of pediatric cholestasis cases and of liver 
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transplantation in children. PFIC has an estimated incidence of 1/50,000 to 1/100,000 
births, with no geographical or gender preference [165]. 
 
 
Table 1 
Description and distinguishing features of the three types of PFIC. Adapted from [166] and 
[165]. 
 
 
Figure 3 
Roles of the hepatocyte transporters mutated in PFIC. PS = phosphatidylserine; PC = 
phosphatidylcholine. 
 
Molecular studies allowed to distinguish 3 forms of PFIC, based on the originating 
genetic lesion. In each case, mutation of a gene encoding for a hepatocellular 
transporter is involved (Table 1, Figure 3). 
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3.3.1 PFIC1 
PFIC1 is due to mutation in the Atp8B1 gene (also called Fic1, familial intrahepatic 
cholestasis 1), which encodes for a P-type ATPase located on the canalicular surface of 
hepatocytes, but also on the apical membrane of cholangiocytes and in organs such as 
intestine and pancreas. 
ATP8B1 has been recently demonstrated to act as a flippase by transporting a 
membrane phospholipid, phosphatidylserine (PS), from the outer to the inner 
membrane leaflet, where PS is generally confined [167]. ATP8B1 activity is probably 
important to control membrane fluidity and to confer resistance to bile salts. Indeed, it 
prevents PS from diluting, along with the excess PC flopped by ABCB4, the 
concentrations on the outer leaflet of sphingolipids and cholesterol, thereby allowing 
the leaflet to form a liquid crystalline phase that would be less sensitive to detergent 
solubilization. 
PFIC1 histological features consist in a generally preserved lobular architecture, and 
are therefore associated to a milder damage with respect to the ones observed for 
PFIC2 and 3 [168]. Accordingly, serum levels of gamma-glutamyltranspeptidase (γ-
GT) and alanine aminotransferase (ALT), enzymes routinely screened as markers of 
hepatic damage, are only slightly elevated in PFIC1 patients. The most remarkable 
finding for PFIC1 is the so-called “Byler bile”, coarse granules of bile accumulating into 
hepatocytes [168]. Although evident, signs of cholestasis are limited to the peri-
canalicular areas. Yet, PFIC1 patients typically develop cirrhosis and severe liver 
failure by their second decade.  
The mechanism linking ATP8B1 mutations to cholestasis consists in a significant 
downregulation of farnesoid X receptor (FXR), a nuclear receptor regulating bile 
metabolism, which determines a downregulation of BSEP, the bile acids transporter in 
the liver, and a parallel upregulation of bile acid synthesis as well as of the apical 
sodium bile salt transporter (ASBT) involved in the bile acids reabsorption in the 
intestine [169]. All together, these events cause bile acid overload in the hepatocytes, 
which is in agreement with the low biliary bile acid concentration measured in patients 
[170]. 
Atp8B1 gene expression occurs in various districts other than liver, for example in 
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enterocytes (at the level of ileum and jejunum), cochlear hair cells in the ear and 
pancreatic acinar cells, and its ablation causes symptoms such as severe diarrhoea, 
hearing loss and pancreatitis, respectively. The fact that Atp8B1 expression is higher 
in intestine than in liver [171] suggests it to be also involved in the bile salts 
enterohepatic cycling. This would explain the chronic diarrhea in a number of PFIC1 
patients. 
 
3.3.2 PFIC2 
The second form of PFIC is due to mutations in the Abcb11 gene, expressing the ATP-
dependent canalicular bile salt export pump (BSEP, also called sister of P-glycoprotein, 
SPGP) in the hepatocyte canalicular membranes. BSEP is the main exporter of primary 
bile acids, and works against considerable concentration gradients. In particular, it 
principally secretes monovalent bile acid species, including primary bile acids such as 
cholic acid (CA) and chenodeoxycholic acid (CDCA) and the secondary bile acid 
deoxycholic acid (DCA). Additionally, it transports ursodeoxycholic acid (UDCA) into 
bile [172]. Collectively, bile salt excretion is necessary for the removal of cholesterol, 
which is water-insoluble: 12-20 g of secreted bile acids are sufficient to eliminate 500 
mg of cholesterol [173]. It is also required for the absorption of other hydrophobic 
substances such as vitamins D, E, K and A, and for the excretion of bilirubin, a 
byproduct of erythrocytes degradation. 
Mutations on Abcb11 therefore impair biliary bile salt secretion, which causes reduced 
bile flow and chronic bile salt accumulation in hepatocytes, progressively leading to 
hepatic damage. Despite linked to extremely low biliary bile salts, PFIC2 is associated 
to normal serum γ-GT and cholesterol levels. Disease typically becomes evident within 
6 months of life, with symptoms including jaundice, growth failure, pruritus, and 
occasionally vitamin K deficiency with consequent severe haemorrhage [165]. The 
most characteristic histologic finding in the early disease is the presence of giant cell 
transformation and different degrees of lobular and periportal inflammation [174]. Of 
note, PFIC2 is the only type of PFIC that has been reported to degenerate into 
hepatocellular carcinoma or cholangiocarcinoma [175-177]. 
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3.3.3 PFIC3 
PFIC3 is caused by genetic defects in the Abcb4 gene (also called Mdr3, the 
orthologous of the gene abrogated in Mdr2-KO mice). As in mouse, MDR3 P-
glycoprotein is a phospholipid floppase involved in biliary PC secretion and is mainly 
expressed in the hepatocyte apical membrane. Consequently, the mechanism of 
cholestatic liver disease in PFIC3 patients is dependent on the absence of biliary 
phospholipids. Human Mdr3 and murine Mdr2 genes share more than 90% homology 
[178], and indeed, when knocked-in to Mdr2-KO mice, human Mdr3 completely 
rescued PC excretion into the bile [179]. 
In contrast to PFIC1 and 2, PFIC3 patients display symptoms of cholestasis within the 
first year only in 1/3 of cases, and might rather become affected later in childhood or 
adolescence. Also, differently from PFIC1 and 2, PFIC3 is characterized by high γGT 
levels and total absence of PC from bile. Symptoms include jaundice, mild pruritus, 
hepato- and splenomegaly, failure to thrive and gastrointestinal bleeding caused by 
portal hypertension [180].  
Histologic examination indicates ductular proliferation, portal fibrosis and mixed 
inflammatory infiltrate. Occasionally, lobular cholestasis and slight giant cell 
transformation can be scored. As the disease progresses, severe portal fibrosis and 
biliary cirrhosis are observed, with interlobular bile ducts found in most portal tracts. 
Cirrhosis eventually progresses to end-stage liver disease, and 50% of patients 
require liver transplantation at 7.5 years [180]. Nevertheless, neither periductal 
fibrosis nor biliary epithelium injury are observed, and no liver tumor has yet been 
reported in association with PFIC3 [159, 165]. 
 
3.3.4 PFIC-HCC: a human counterpart for Mdr2-KO HCC 
As previously mentioned, PFIC2 is the only type of PFIC that has been associated to 
hepatocarcinoma development to date. In particular, PFIC2 patients have an increased 
risk of developing HCC at age of two years equal to 5-10% [177].  
Interestingly, the cholestatic phenotype displayed by Abcb11-KO mice is less severe 
than the one described in PFIC2 patients, and is not generally associated to HCC 
development [181]. In particular, these animals display liver injury with high mortality 
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rate only upon feeding with a cholate-containing diet [182]. This is attributed to the 
more hydrophilic bile salts pool found in mice, which includes muricholic acid and 
atypical species such as 24-tetrahydroxy bile acids (not found in humans) [182]. 
Nevertheless, despite the striking reduction in the cholic acid export observed in these 
mice, the total output of bile salts is almost unaffected due to the parallel upregulation 
of Abcb1a, a different ABC transporter that seems to compensate for Abcb11 absence 
in mice, but not in PFIC2 patients [183, 184]. 
PFIC-HCC tumors are generally characterized by increased levels of α-fetoprotein 
(AFP) and nuclear accumulation of p53 protein, but no nuclear accumulation of β-
catenin [177]. Recently, development of multiple, well-differentiated dysplastic 
nodules in a PFIC2 patient has been reported [175], suggesting PFIC 
hepatocarcinogenic process to follow a discrete progression through dysplasia, 
adenoma and HCC similarly to what described for Mdr2-KO mice. 
PFIC-HCC commonly stems from an early histologic pattern including lobular/portal 
inflammation, along with giant cell transformation and hepatocellular swelling and 
necrosis [174]. Also this hepatitis-like condition closely resembles the persistent portal 
inflammatory reaction observed at the early stages of Mdr2-KO disease.  
Therefore, despite differences in some of the histopathologic features acquired by the 
murine and the human disease, HCC lesions developed by Mdr2-KO mice and PFIC2 
patients share a very close etiologic background, deriving from a chronic inflammatory 
setting that gives way to a step-wise tumorigenic process. 
 
4. Aims of the project 
Tumor formation and progression are accompanied by genetic, epigenetic and 
transcriptional alterations, some of which are directly and critically involved in bringing 
about the abnormal properties of tumor cells. Nevertheless, how these different layers 
of genome organization and function evolve in emerging and established tumors, 
influence each other, and impact on cellular physiology and tumor progression, is 
essentially unknown. Lack of such integrated knowledge is a major hurdle to a 
definitive understanding of the molecular bases of cancer development, and thus to 
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the development of mechanism-based therapies. 
Indeed, most of the systems biology-based models of cancer produced so far rely on a 
single level of complexity (e.g. transcriptome) [185, 186]. Furthermore, they take into 
consideration only one step (the terminal stage) of tumorigenesis, where the essential 
driving events are usually outnumbered by secondary (bystander) genetic and 
epigenetic alterations. 
This project aimed at dissecting the events occurring at each temporal step of a 
tumorigenic process at the level of genetic and epigenetic modifications, in order to 
obtain information that will be necessary to determine their temporal relationship and 
interplay. 
To this respect, we found particularly interesting to characterize the genetic and 
epigenetic phenomena leading to cancer formation from a chronic inflammatory 
condition. Indeed, as both inflammation and epigenetic alterations are acknowledged 
as early events of a tumorigenic process, and since the mechanistic link between 
inflammation and tumor onset is still unclear, we wanted to understand whether 
inflammation could lead to cancer development by causing a progressive disruption of 
epigenetic patterns, and how would this impact over the genome. 
For these purposes, we chose the liver as a model organ for several reasons: (1) the 
relative homogeneity of the tissue (in which over 70% of the cells are hepatocytes); 
(2) the large amount of material available, that would allow for multiple parallel 
experimental analyses; (3) the availability of several mouse models of inflammation-
driven liver cancer. To this respect, the existence of clearly identifiable pathological 
phases, along with the independence from external mutagenic stimuli, makes the 
Mdr2-knockout mice a suitable model for the study of the genetic and epigenetic 
variations occurring over time during a tumorigenic process. 
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MATERIALS AND METHODS 
 
Murine liver tissues and primary hepatocytes preparation 
Founders of the FVB.129P2-Abcb4tm1Bor (Mdr2-KO) and FVB.129P2-Abcb4wt (Mdr2-WT) 
mice were purchased from The Jackson Laboratory. During initial pathological stages 
(inflammation, dysplasia), or on Mdr2-WT animals, downstream manipulations have 
been carried out on purified populations of hepatocytes obtained via collagenase liver 
perfusion, using a two-step protocol adapted from the original procedure proposed by 
Berry and Friend [187] and subsequently modified by Seglen [188]. Upon appearance 
of incapsulated lesions, at the age of 10 to 16 months, each nodule or liver tissue 
sample from KO animals was divided into three portions, one being snap frozen for 
DNA/RNA extraction, a second one fixed in 4% formaldehyde and further processed 
for histologic analysis, and a third one finely chopped and fixed in 1% formaldehyde-
PBS for 15 minutes for chromatin immunoprecipitation. As a non-tumoral counterpart 
from the each individual, kidneys were collected and frozen. 
 
Mouse histology 
Livers portions assigned to histological assessment were fixed in 4% formaldehyde 
overnight. The next day the sample was washed in 70% ethanol and submitted for 
paraffin embedding. 5 um sections were stained with hematoxilin/eosin, and 
submitted for inspection to a mouse pathologist (Enrico Radaelli, VIB Center for the 
Biology of Disease, KU Leuven Center for Human Genetics, Belgium). The histological 
composition of grossly detectable hepatic nodules, along with the composition of the 
non-tumoral surrounding tissues, was semi-quantitatively determined based on the 
classification criteria reported in [189]. 
 
Mouse immunohistochemistry 
Anti-CD3 immunostains were performed as previously described [160], with minor 
modifications. Briefly, 5 um sections were de-waxed and re-hydrated through an 
ethanol scale, heated in 1mM EDTA pH 8.0 in a water bath at 95°C for 25 minutes for 
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antigen de-masking and left to cool down for 20 min. After 5 minutes treatment with 
3% H2O2, slides were incubated with rat monoclonal biotinilated CD3 antibody 
(Serotec) diluted 1:50 in a blocking solution (2% BSA, 2% goat serum, 0.02% 
Tween20, in TBS 1x) overnight at 4°C, washed three times with TBS 1x, and 
developed with DAB (DAKO) for 20 minutes. Slides were finally counterstained with 
hematoxylin, de-hydrated through alcoholic scale and mounted with Eukitt. 
 
DNA, RNA and cDNA preparation 
DNA from frozen hepatocytes was obtained using the DNeasy Blood and Tissue Kit 
(Qiagen). Frozen tissue samples were homogenized with a dounce homogenizer or 
with GentleMACS Dissociator (Miltenyi Biotec), depending on the tissue volume, prior 
to column extraction. DNA from formalin-fixed, paraffin-embedded (FFPE) samples 
was purified with the AllPrep DNA/RNA FFPE kit (Qiagen). RNA was extracted in Trizol 
(Invitrogen) using the RNeasy Mini Kit (Qiagen). 0.5 ug of total RNA was used for 
cDNA synthesis (using the ImProm-II Reverse Transcriptase, Promega), and 1 µl of 
the obtained cDNA was generally used as template for qPCR expression analyses. 
Quantification was performed on Nanodrop, and quality was assessed on Bioanalyzer 
(Agilent). 
 
Chromatin Immunoprecipitation (ChIP) 
ChIP was carried out as previously described [190]. Briefly, 2.5 millions of perfused 
fixed hepatocytes, or 350 mg of liver/tumoral fixed tissue have been used for each 
ChIP. Chopped tissue samples were further homogenized with GentleMACS Dissociator 
(Miltenyi Biotec) prior to lysis. Hepatocytes or homogenized tissues were processed 
with a two-step lysis protocol for cellular and nuclear membranes disruption, followed 
by chromatin shearing by sonication. Each lysate was then immunoprecipitated with 5 
ug of the following antibodies: H3K27Ac (Abcam, ab4729), H3K4me1 (Abcam, 
ab8895), or H3K4me3 (Active Motif, #39159).  
Antibodies were prebound overnight to 100 ul of G protein-coupled paramagnetic 
beads (Dynabeads) in PBS/BSA 0.5%. Beads were then added to lysates, and 
incubation was allowed to proceed overnight. Beads were washed six times in a 
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modified RIPA buffer (50 mM HEPES pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 
and 0.7% Na-deoxycholate) and once in TE containing 50 mM NaCl. DNA was eluted in 
TE containing 2% SDS and crosslinks reversed by incubation overnight at 65°C. DNA 
was then purified by Qiaquick columns (Qiagen) and quantified with PicoGreen 
(Invitrogen).  
ChIP validation by qPCR has been done using 1 ul of purified DNA for amplification on 
an Applied Biosystems 7500 Fast Real-time PCR system (SYBR Green, Applied 
Biosystems). Primers used for ChIP-qPCR are in reported in Table 2. 
ChIP DNA was prepared for HiSeq2000 sequencing following standard protocols, with 
a 36bp single end setting. 
 
 
Table 2 
List of primers used in this work. Type of analysis for which each primer couple has been used is 
indicated (top left column). H3K4me1 positive control primers have been designed on 
H3K4me1-rich regions according to published dataset (GEO accession n. GSM594586). 
H3K4me3 positive control primers have been designed around the TSS of genes expressed in 
liver (SCD1 and Cyp27A, respectively). H3K4me1/3 negative control primers have been 
designed on gene desert regions. 
 
ChIPseq analyses 
Short reads obtained either from Illumina HiSeq 2000 were quality-filtered according 
to the Illumina pipeline. Analysis of the data sets, beginning with alignment of the 
reads to the reference mm9 genome, was automated using the Fish the ChIPs pipeline 
[191]. All the reads with a unique match to the genome with two or fewer mismatches 
(-m 1 –v 2) were retained. Peak calling was performed using MACS v1.4 [192] with 
default parameters and bw = 300. Each IP was compared to input DNA derived from a 
WT liver.  
Type of analysis Type of primers Forward Reverse
H3K4me1 positive control 1 AGGCTCACAGAACCCAGAGA TCACAAAGCATGCTCTCCAC
H3K4me1 positive control 2 AGATGTCAGTTTGGGGTTGC GTTGTCAGAAGGGCAGGTTC
H3K4me3 positive control 1 AGAGTCAGGAGGGCAGGTTT GCTCACCTCTTGGAGCATGT
H3K4me3 positive control 2 AACTCTTGGCTTCTCGGGCA ACCCTCCGTACTCTCCTGTG
H3K4me1/3 negative control GCCAAAGTGGAGTGGAAAGA GCAGGTTCTGGAAACTGGAA
MKK7 AGGATCGACCTCAACTTGGA GCTCTCTGAGGATGGTGAGC
Nucleolin TGGAGATCACAACAGCCAAA CTTCTTCCGTTTTCCAGGTGExpression
ChIP-qPCR
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To identify peaks increased in our inflamed or tumor samples datasets over the WT 
datasets, we used MACS [192]. 
 
Principal component analysis (PCA) 
Principal component analysis is a statistical method that can be applied to a high-
dimension dataset in order to reduce its dimensionality to a few original data 
dimensions: the principal components of the dataset [193]. In this case, PCA was 
used to reduce the dimensionality of tags number in all peaks (MACS score ≥50) in 
each samples considered to 2 main principal components, which accounts for a high 
percentage of the total variability. The number of tags has been normalized among 
samples prior to PCA, as samples had a different number of total starting tags (Table 
S 1). 
 
Gene ontology analysis 
For each timepoint sample group, GREAT 2.0.2 [194] was run against the whole mm9 
genome (NCBI build 37 (UCSC mm9, Jul/2007)) as background, and results were 
summarized as a heatmap. We considered all the terms significantly enriched in at 
least one comparison (Hypergeometric FDR% ≤0.05) for the Biological Process 
ontology. FDR p-values were (-)log2-transformed in order to obtain positive scores. 
Results were then clustered using an hierarchical clustering algorithm (hclust R 2.15.1 
function: method=average, Pearson correlation as a measure of the distance). Finally, 
scores were saturated (quantile = 0.95) and visualized (R heatmap.2 function). 
 
Motifs enrichment analysis 
In order to identify over-represented motifs corresponding to known TF binding sites, 
for H3K27Ac common induced peaks we used PSCAN [195] keeping H3K27Ac peaks 
that are unchanged in the different samples comparisons as background. Regions 
were scanned with 597 models (position weight matrices, PWM) collected from the 
literature [196-200].  
To assess motif occurrence on the same datasets, we used Find individual motif 
occurrences (FIMO), a tool of the MEME Suit aimed at scanning a sequence database 
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for the occurrence of a desired list of motifs [201]. The list of matrices used as query 
for FIMO was derived from the top ranking PWM identified by PSCAN. We selected for 
occurrences with a minimum p-value of 10-4, and searched for motifs at +/-500 bp 
around each peak center. 
 
Target enrichment, whole exome, and whole genome sequencing  
We performed target enrichment in order to enrich our genomic samples for desired 
sequences (in our case, the whole exome). This technique is based on the 
hybridization of the target sequences with commercial biotinylated RNA baits, 
selections of the hybrids with streptavidin and DNA fragments purification. For Mdr2-
KO WES, SureSelect XT Mouse All Exon kit (Agilent) was used to target 21,543 mouse 
genes (Table S 6). As for human WES, target capture was done on six tumors and 
normal counterparts (Table S 10) using the SureSelect XT Human All Exon V4 kit 
(Agilent) targeting 20,965 human genes. Sample MB was excluded from whole exome 
sequencing because of the low tumor content (Table S 9).  
Target enrichment was performed following the manufacturer’s protocol with slight 
modifications. Briefly, around 3 ug of genomic DNA were sheared using an ultrasonic 
disruptor (Bioruptor, Diagenode) or using Adaptive Focused Acoustics technology 
(Covaris). After library preparation with Illumina DNA Sample Prep Kit, 200-250 bp 
fragments were selected and purified by gel extraction, or using the minelute PCR 
purification kit (Qiagen), or the Agencourt AMPure PCR Purification system (Beckman 
Coulter). Fragments were further amplified with 10 cycles of PCR and 500 ng were 
hybridized with each bait library. DNA capture was followed by paired-read cluster 
generation on the Cluster Station (Illumina). Libraries were sequenced using half lane 
of Illumina HiSeq2000 per sample, with 76 bp or 101 bp paired-end protocol, except 
for the tumoral sample of patient 7860, where one entire lane was used due to high 
levels of DNA degradation (Table S 9). 
For whole genome sequencing, around 1 ug of mouse genomic DNA was sheared in 
400-500 bp fragments using an ultrasonic disruptor (Bioruptor, Diagenode). Library 
was prepared with Illumina Paired-End DNA Sample Prep Kit. The libraries obtained 
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were sequenced using one lane of Illumina HiSeq2000 per sample, with the 101 bp 
paired-end protocol. Details on sequencing setting and throughput are available in 
Table S 6. 
 
Alignment, variant calling and mutation validation  
Paired-end sequencing reads from each tumor and normal were mapped to the mouse 
genome (NCBI37/mm9) or to the human genome (GRCh37/hg19) using Novoalign 
(http://novocraft.com). A maximum of three mismatches per read were allowed and 
duplicated reads were removed using rmdup of SAMtools [202]. All reads uniquely 
mapping within 75-100 bp of the targeted regions were considered on target and 
retained for further analysis. 
Somatic point mutations are estimated to be rare events (roughly 1 per megabase), 
which imposes the requirement for a very low technical error rate to minimize false 
positive calls. On the other hand, tumor heterogeneity and sample contaminations 
with non-tumoral (stromal) cells might be frequent sources of false negatives [203]. 
In order to increase the sensitivity and specificity of mutation calling, tumor 
sequencing needs to reach a degree of coverage (i.e., the “covering” of the reference 
genome by the sequences generated from the analysed samples) of around 15-30x in 
whole genome experiments and 100x for whole exomes. Details on the coverage of 
our samples are found in Table S 6 and Table S 10.  
Single nucleotide variants (SNVs) and indels were identified using SAMtools [202] and 
Varscan 2 [204] and retained if covered by at least 10 reads and with frequency 
≥20%. Somatic mutations and indels were identified as tumor-specific mutations with 
coverage ≥5x and frequency <10% in the normal counterpart. All retained SNVs and 
indels underwent manual inspection.  
Genomic regions surrounding 26 random mutations were amplified by PCR using Taq 
DNA Polymerase (Qiagen) in the tumor and corresponding normal and Sanger 
sequenced in both directions on a 3730xl DNA Analyzer (Applied Biosystems) using 
dRhodamine chemistry. Out of 26 randomly selected variants, 25 were confirmed (> 
96% accuracy). 
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CNV calling in mouse WES and WGS data  
To detect CNVs on WES data, we exploited the difference in sequencing coverage 
between tumors and normal counterparts, based on the assumption that amplified 
genes have higher coverage in the tumors compared to their normal counterpart, 
whereas deleted genes have lower coverage (Sinha et al., submitted). After coverage 
normalization, the log2ratio of the fold change between tumor and normal was 
measured for each gene and used to assess the differences in copy number, setting as 
thresholds for amplification log2ratio = 0.5 (corresponding to >1.5 fold change), and 
for deletion log2ratio = -1.0 (corresponding to <0.5 fold change), respectively. In 
order to remove possible false positives due to particularly low coverage of some 
genes, we used PCA. Assuming a normal distribution of the variation in coverage 
between tumor and normal, we estimated a confidence interval based on the 
comparison between the CNVs detected in the whole genome and in the whole exome 
of the sample 60400/1. The optimal value that minimized false positive and 
maximized true positive was 90% confidence interval. Genes at the left tail of the 
distribution (above 90% PCA confidence interval) and with log2ratio ≥ 0.5 were 
considered as amplified, while genes at the right tail of the distribution (below 90% 
PCA confidence interval) and log2ratio ≤-1.0 were considered as deleted. CNVs were 
counted only for genes in the autosomal chromosomes. The genes in chromosome X 
were used as internal control for assessing amplifications while comparing female 
lesions with the normal male sample. 
Copy number analysis on the WGS data was performed using CNVnator v. 0.2.5 [205] 
with sequence bins of 300bp. Regions with low confidence (p-value <0.05), composed 
of ≥65% repeats and/or gap, or covered for ≤30% of high quality mapping reads 
were removed. Furthermore, CNVs were retained only if their length spanning at least 
3 consecutive bins was >1000bp. CNVs were identified as somatic if there was ≤ 5% 
overlap in length between tumor copy number regions and matched normal. To 
identify the CNV boundary, adjacent regions with the same copy number state were 
merged.  
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TaqMan copy number assay 
Validation of putative copy number variations was performed by qPCR using TaqMan 
Copy Number Assay on a 7900HT Fast Real-Time PCR System (Applied Biosystems) 
with Sequence Detection Systems Software 2.2.2. TaqMan probes designed by the 
manufacturer were used for the experiment. Tert (Applied Biosystems, part number 
4458373) was used as a reference. All samples were plated in quadruplicates with 
approximately 20 ng of DNA for each reaction. Copy-number calling was done with 
CopyCaller v2.0 (Applied Biosystems), using the matched normal tissue as a 
reference. 
 
Statistical and network analyses 
The probability that Map2k7 amplification occurred at frequency higher than expected 
was computed by binomial test, using the fraction of all genes undergoing CNVs 
(2,430, 11% of the total targeted genes) as expectation.  
Human protein-protein interaction network (13,531 proteins and 98,492 binary 
interactions) and the primary interactors of JNK (14 proteins) were retrieved from 
NCG3.0 [206]. 1,782 orthologs in the human network of the 3,095 mouse genes that 
were overall altered in the 14 analysed tumors were identified using MGI [207] and 
eggNOG 2.0 [208]. The distance of these proteins from the 14 JNK primary interactors 
was calculated using the function shortest.paths of the R IGRAPH package version 0.6 
(http://igraph.sourceforge.net). Fourteen genes with the same degree (number of 
connections) of the JNK primary interactors were randomly extracted from the 
network for 10,000 times and their distance to the 1,782 proteins was measured to 
obtain a distribution of expected distances. Observed and expected distributions were 
compared using the Wilcoxon test.  
 
Treatment with SP600125 JNK inhibitor 
Twenty-three Mdr2-KO mice, 13 to 14 months old, were randomly divided into two 
groups and treated with SP600125 (anthra(1,9-cd)pyrazol-6(2H)-one) (Calbiochem), 
or vehicle. Vehicle for SP600125, diluted in DMSO, was 40% polyethylene glycol (PEG, 
Sigma) in PBS. Treatments (60 mg per dose) were administered intraperitoneally 3 
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times a week for a total of 3 weeks. Mice were sacrificed one week after the end of the 
treatment, and all detectable nodules were collected for DNA extraction and 
histological analysis. Grossly detectable hepatic nodules were counted and measured 
with a caliper. 
 
Human sample description 
Samples used in the study were obtained from frozen or FFPE material from 7 children 
diagnosed with PFIC2-related HCC (Table S 9). All specimens were obtained at 
native-liver hepatectomy during transplantation. Background liver in all patients 
exhibited parenchymal rather than portal-tract cholestasis, with BSEP expression 
detectable in none.  Some patients displayed frank cirrhosis, others only variable 
degrees of fibrosis (Table S 9). Samples 7860 175, 1790, 2896, and MB came from 
single uncapsulated masses, while sample 23836 derived from one of several HCC 
within a single liver. Sample HB4R was an intrahepatic relapse that developed 6 years 
after liver transplantation, outside the graft. The patient was treated with 
chemotherapy before relapse surgical resection. In all samples, non-neoplastic liver 
tissues from the same patients were used as matching normal references.  
 
Functional annotation of mutated genes 
The list of genes affected by mutations was intersected with the genes know to be 
recurrently mutated in HCC (TP53, CTNNB1, ARID1A, ARID2, AXIN1, PRS6KA3, 
VCAM1, CDK14, TERT, MLL4, CCNE1) [209] and with the list of 537 genes known to 
have a causative role in human cancer [210].  
Expression levels of mutated genes in normal liver were inferred from publicly 
available data [211, 212]. Starting from the raw CEL files of the two experiments 
(GSE2361 and GSE1133), data were normalized and analysed using the MAS5 
algorithm [213]. The expression levels for each gene in the liver was calculated as the 
mean value between all gene probes with detection p-value <0.05. If all probes of a 
gene had p-value >0.05, the gene was considered not expressed. The normalized 
expression level was then measured as the gene expression level over the median 
expression of all genes in the liver. Genes with expression higher than the median 
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were considered as highly expressed, while all genes with expression lower than the 
median were defined as lowly expressed.  
 
SNP array and copy number calling in the human samples 
Genomic DNA extracted from FFPE samples and from frozen samples was processed 
according to Infinium® HD assay ultra manual. DNA from FFPE samples was restored 
before SNP array processing according to Infinium HD FFPE restore protocol. All seven 
human tumors and matched normal were assayed using Illumina HumanOmniExpress-
12 v1.0 and image data were scanned using BeadArray reader. Intensity and 
genotype data were extracted for copy number variation analysis after normalizing 
raw fluorescent signals using Illumina Genome Studio.  
Copy number variation analysis was performed using ASCAT (version 2.1) [214].  
To identify amplified and deleted genes, the genomic coordinates of the CNV regions 
in each sample were intersected with those of 20,965 human genes contained in the 
SureSelect XT Human All Exon V4 kit (Agilent). A gene was considered as amplified or 
deleted if ≥ 80% of its length was contained in a CNV region.  
 
Fluorescence in situ hybridization (FISH) 
Validation of amplification of chromosome 19 in sample 23836 has been performed by 
two-color FISH using a Vysis LSI 19q13 SpectrumOrange/ 19p13 SpectrumGreen 
probe (Abbott), according to manufacturer’s instructions. 2 um FFPE slides from tumor 
and normal liver of patient 23286 were first deparaffinised in xylene, washed in 100% 
ethanol, incubated in 1x SSC (0.3 M sodium chloride, 0.03 M sodium citrate) pH 6.0 at 
80°C for 20 minutes for de-masking, and digested with pepsin (0.5 mg/ml in 0.2 N 
HCl, pH 1.0; Protease and Protease Buffer II, Abbott) for 17 minutes at 37°C. Samples 
were then washed in 2x SSC, dehydrated in 70, 95 and 100% ethanol, and air dried.  
10 ul of probe were directly applied on each slide, topped with a coverglass, and 
sealed with rubber cement. Slides were placed in a HYBrite (Abbott), and the probe 
was left to denature 1 minute at 85°C, followed by an overnight hybridization at 37°C. 
Coverglasses were finally removed and slides were washed twice in 2x SSC with 0.1% 
NP-40 at RT, once in 0.4x SSC with 0.3% NP-40 at 73°C, and once again in 2x SSC 
 53 
with 0.1% NP-40 at RT. After counterstaining with DAPI (Sigma), FISH signals were 
scored with an Olympus BX61 upright microscope, using a 100x objective.  
 
 
 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 55 
RESULTS 
 
1. Epigenomic analyses 
1.1 Histological characterization of Mdr2-WT and –KO samples  
In order to identify possible changes in epigenomic patterns along the Mdr2-KO 
tumorigenic process, we generated a panel of chromatin immunoprecipitations (ChIP) 
followed by NGS (ChIPseq) on liver samples prepared from different time points. In 
particular, we considered at least 3 samples of adenoma, low grade HCC (≤60% 
carcinoma content) and high grade HCC (≥80% carcinoma content), all coming from 
different individuals 11 to 16 months old. These samples have been compared to age-
matched WT livers, and to samples of 8 months old inflamed, non-tumoral livers 
(Table 3).  
Pathological inspection of the selected samples identified an entire spectrum of 
histological situations. From the baseline, represented by normal hepatic parenchyma 
without any microscopic lesion, the disease starts from the occurrence of adaptive, 
degenerative or reactive features of hepatocytes in response to an inflammatory 
condition. These changes include hepatocellular atrophy, regenerative hepatocellular 
hyperplasia, hyperplasia of oval cells or bile ducts, hepatocellular degeneration or 
necrosis, inflammatory or fibroproliferative changes. Progression leads to the 
development of foci of preneoplastic cellular alteration, non-incapsulated but discrete 
lesions demarcated from the adjacent tissue by virtue of different (generally 
increased) cell size and peculiar staining (which classifies them as basophilic, 
eosinophilic, amphophilic, clear cell or vacuolated). Adenomas are distinguished as 
incapsulated and often bigger (and macroscopically visible) lesions, with slight signs of 
cytologic atypia (coarsely clumped chromatin, large nucleoli, increased nucleus to 
cytoplasm ratio, cytoplasmic basophilia). The last stage of the disease is characterized 
by the appearance of carcinoma, which could display peculiar features such as 
vascularization, aberrant mitotic figures, moderate to marked cytologic atypia, internal 
necrosis or hemorrage and typical cellular architecture (with trabecular, acinar or solid 
patterns) (Table 3). 
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Table 3 
Histologic description of samples processed for ChIPseq analyses. Hepatocyte preparation via 
collagenase perfusion is not compatible with material being processed for histologic 
examination, therefore for perfused samples histologic composition was not assessed. One 
sample of tissue processed without perfusion has been included in each set, in order to verify 
whether possible differences could be ascribed to the preparation protocol rather than to the 
histological content. In the case the degree of variability (dependent on the fact we are 
considering different tissues from different individuals) would have been too high to allow a 
proper statistical separation among different categories, we included a pool of all WT and all 
high grade HCC samples. N.A. = not applicable. 
 
Hepatocellular carcinomas develop within adenomas, implying that each nodule is a 
mixture of adenoma and carcinoma content, whose proportion has been carefully 
evaluated. Furthermore, in order to estimate local invasiveness (one of the most 
reliable indicator of tumor malignancy), it is necessary to pathologically inspect also 
the tissue surrounding the lesions (i.e. normal, inflamed or pre-neoplastic tissue). For 
this reason, each nodular specimen assigned to histologic analysis includes a non-
tumoral portion (Table 3, Figure 4). As for the genetic and epigenetic analyses, 
however, in order to avoid confounding results due to contamination by surrounding 
inflamed, non-tumoral tissue, each incapsulated lesion (adenoma or HCC) has been 
carefully excised, cleaned from surrounding material and individually processed. 
Type Sample Gender Preparation % normal % degenerative changes
% preneoplastic 
foci % adenoma % carcinoma
1 F Perfusion N.A. N.A. N.A. N.A. N.A.
2 M Perfusion N.A. N.A. N.A. N.A. N.A.
3 M Perfusion N.A. N.A. N.A. N.A. N.A.
4 M Tissue 100 0 0 0 0
N.A. N.A. N.A. N.A. N.A. N.A.
1 M Tissue 0 90 10 0 0
2 F Perfusion N.A. N.A. N.A. N.A. N.A.
3 F Perfusion N.A. N.A. N.A. N.A. N.A.
4 F Perfusion N.A. N.A. N.A. N.A. N.A.
1 F Tissue 0 0 0 100 0
2 F Tissue 0 0 0 100 0
3 F Tissue 0 20 10 70 0
4 F Tissue 0 20 10 70 0
1 M Tissue 0 30 10 50 10
2 F Tissue 0 30 10 50 20
3 M Tissue 0 30 0 40 20
4 F Tissue 0 20 10 30 40
5 F Tissue 0 10 0 30 60
1 F Tissue 0 10 0 0 90
2 F Tissue 0 10 0 0 90
3 M Tissue 0 0 0 20 80
Tissue N.A. N.A. N.A. N.A. N.A.
Pool (samples 1, 2, 3, 4)
HCC high grade
Pool (samples 1, 2, 3)
Inflamed
Adenoma
HCC low grade
WT
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Figure 4 
Histologic assessment of inflammatory infiltrates presence in parenchymal liver tissues along 
Mdr2-KO pathogenesis. 
(A) Semi-quantitative score of inflammatory changes observed in the tissues used for ChIPseq. 
Changes were characterized by focal infiltrates of inflammatory cells including one or more of 
the following cell types: lymphocytes, plasma cells, macrophages (often pigmented) and 
A 
B 
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neutrophils. Hematoxilin/eosin sections were scanned in at 10x magnification and for each 
histologic component (expressed as a percentage) identified in the sample the degree of 
inflammatory changes was indicated as – (average number of inflammatory foci ≤ 2 per 
miscoscopic 10x field), + (average number of inflammatory foci > 2 and ≤ 5 per miscoscopic 
10x field), ++ (average number of inflammatory foci > 5 per miscoscopic 10x field). 
(B) Representative microscopic fields of some analyzed specimens. All pictures have been 
captured at 10x magnification. Arrows denote inflammatory cell foci. 
 
In the case of WT and inflamed organs, where the whole liver had to be taken but 
contamination could result from non-parenchymal cell populations (e.g. Kupffer cells, 
endothelial cells), collagenase perfusion has been applied to obtain a single-cell 
suspension that has been purified by centrifugation and thereby enriched for 
hepatocytes (Fig. S4).  
On the other hand, inside nodular formations (adenoma and carcinoma), pathological 
examination estimated a low degree of inflammatory cells infiltration, which was 
comparable to the one found in the livers of healthy individuals (Figure 4). 
 
1.2 Statistical analysis of the variability among Mdr2 ChIPseq datasets 
Our primary interest was to identify transcription factors (TFs) becoming activated 
during the tumorigenic process, and that could thus provide hints on the principal 
mechanisms accompanying the generation of cancer. For this reason we chose to 
follow a “reverse epigenetics” approach, by focusing on the profiling of H3K27Ac 
modification as a mark of active regions, that could suggest TF potentially relevant for 
disease progression [215]. To this purpose, we performed a set of ChIPseqs against 
H3K27Ac on inflamed, adenoma, low grade and high-grade HCC samples, to be 
compared with ChIPseqs on WT samples. Furthermore, we were interested in 
searching for changes at the level of regulatory regions such as active promoters or 
distal elements (enhancers). For this reason, we generated ChIPseq datasets to profile 
H3K4me3 (a mark for active transcription start sites, TSS) and H3K4me1 (enriched on 
enhancers) on WT, inflamed and low-grade HCC samples [216]. 
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Figure 5 
Principal component analysis of Mdr2-KO ChIPseq data sets. 
 
As a first step, we wanted to check whether the degree of variability among samples 
was too high to allow discrimination of different disease stages. In order to reduce the 
complexity of these data sets, we applied a principal component analysis (PCA), a 
statistical procedure aimed at extrapolating a number of dimensions as small as 
possible that would describe the original data set while maintaining much of its 
variance. In particular, PCA converts a number of possibly correlated variables into a 
number of uncorrelated variables (or principal components, PCs) by orthogonal 
transformation. In this system, the first PC includes as much variability as possible 
(and therefore, it is usually the most informative parameter), and each subsequent PC 
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describes as much of the remaining variability as possible (provided it is orthogonal to 
the preceding PCs) [193]. Usually, the first two PC provide a simplified but sufficiently 
informative view of the data. 
In this case, PCA was used to reduce the dimensionality of tags number to 2 main 
components. By applying a PCA to the ChIPseq data for H3K4me1 and H3K4me3, we 
observed that in both cases samples belonging to different disease steps were 
generally clustering separately (Figure 5B). In the case of H3K27Ac, for which data 
for two additional categories (“adenoma” and “high grade HCC”) was available, 
separation was still generally neat (Figure 5C). 
Based on PCA results, for further analyses we excluded as “outliers” samples failing to 
cluster close to the bulk of each category. 
 
1.3 Assessment of common H3K27Ac changes at each timepoint along Mdr2 
tumorigenic process 
In order to find epigenomic changes characteristic of each disease stage, for each 
modification that was considered we calculated the number of induced or repressed 
peaks over the WT that were in common to all samples of a given group (Table 4). 
The highest number of induced or repressed peaks (with respect to WT) displayed by 
all samples at a given time point was found for H3K27Ac, and particularly for induced 
peaks, indicating that this mark is subject to the highest variability specifically 
associated to the Mdr2-KO tumorigenic process. On the contrary, the number of 
common induced or repressed H3K4me1 and me3 peaks is very low both for inflamed 
and low grade HCC samples.  
These data suggests that H3K27Ac-induced regions are possibly most informative on 
the Mdr2-KO pathogenesis, and for this reason we chose to focus further analyses on 
this modification. 
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Table 4 
Number of induced or repressed H3K27Ac, H3K4me1 or H3K4me3 ChIPseq peaks that are in 
common to each disease timepoint. N.A. = not applicable. 
 
 
 
Figure 6 
Number of peaks for Mdr2-KO H3K27Ac ChIPseq samples. Numbers of WT samples (in blue) are 
reported at the bottom of each bar. Dashed black lines indicate the number of common peaks of 
each sample when compared to each of the WT samples, while dashed blue lines indicate 
common peaks among all samples compared to all WTs. 
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Taking a closer look, by normalizing the number of peaks of each sample with the 
number of peaks of each WT sample, generally half of the peaks are common to all 4 
comparisons with WTs suggesting that, as expected, WT samples are characterized by 
a low degree of variability (Figure 6).  However, the number of peaks common to all 
the comparisons is much lower, underlying the high variability in the evolution of liver 
cancer. Nevertheless, peaks found to be common to all the comparisons within each 
category can be considered as stage-specific peaks, and were therefore taken in 
consideration for downstream analyses. In particular, as previously discussed (Table 
4), we focused on H3K27Ac induced peaks that were common to all samples in each 
timepoint. 
In order to evaluate whether enhancers that became hyperacetylated with respect to 
the WT (i.e., enhancers that became active) also displayed changes in H3K4me1, we 
analyzed the H3K4me1 status on the common regions that acquired H3K27Ac in 
inflamed or low grade HCC samples (Figure 7). Both in the case of inflamed and low 
grade HCC timepoints, we observed that regions gaining H3K27Ac were undergoing 
changes in methylation levels, and in particular they were generally acquiring 
H3K4me1 (Figure 7). 
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Figure 7 
H3K4me1 status at H3K27Ac common induced ChIPseq peaks in Mdr2-KO inflamed and low 
grade HCC samples. Regions associated to H3K27Ac common induced peaks were observed in 
H3K27Ac and, in parallel, in H3K4me1 ChIPseq samples, as indicated on bottom. Rows were 
ordered by decreasing number of tags according to the first inflamed (left heatmap) or HCC 
(right heatmap) sample. 
 
1.4 Gene ontology analysis on H3K27Ac common induced peaks-associated 
genes 
We next wanted to score H3K27Ac common induced peaks for associated functional 
categories of the nearby genes. To this end, we performed a gene ontology (GO) 
analysis using the “genomic regions enrichment of annotations tool” (GREAT) [194], 
using WT samples as reference. GREAT failed to cluster samples according to the 
tumorigenesis timepoint classes (Figure 8). However, a strong inter-class functional 
enrichment was observed for biological processes associated to inflammation and 
immune response (Figure 8). This suggests an activation of machineries involved in 
immunity and inflammatory components, which would start from the inflammation  
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Figure 8 
GREAT analysis of the biological processes linked to genes associated with H3K27Ac gain in 
Mdr2-KO ChIPseq samples. Close-ups inserts highlight affected categories that are common to 
the majority of samples. 
 
phase and would be retained until end-stage tumor, despite the absence of non-
parenchymal, inflammatory cells in tumoral samples (Figure 4).  
 
1.5 Motifs enrichment analysis on H3K27Ac common induced peaks 
In order to identify over-represented motifs representing known TF binding sites in 
H3K27Ac common induced peaks, we used PSCAN [195]. H3K27Ac peaks that did not 
vary along the different samples were used as background for comparison.  
At all time points, the most enriched matrices corresponded to binding sites for the 
activator protein 1 (AP-1) TF family members (such as Jun, JunB, JunD, JDP2, Fos, 
FosB; Table 5). AP-1 TFs are heterodimers composed of members of the Fos (FBJ 
murine osteosarcoma viral oncogene homolog), Jun, JDP (Jun-dimerizing partner) or 
ATF (activating transcription factor) subfamilies [217]. They are activated in response 
to a variety of stimuli, including cell stress and inflammation, exposure to cytokines or 
growth factors and infection, and control cell proliferation and apoptosis [218]. 
Therefore, the finding that common H3K27Ac induced peaks are enriched for AP-1 
matrices is in agreement with the general activation of inflammatory pathways 
resulting from the GO analysis (Figure 8). 
The second class of transcription factors whose matrices were enriched in H3K27Ac 
common induced peaks was the erythroblast transformation-specific (ETS) TF family. 
Predominant ETS matrices were the ones associated to the SPI subfamily (from spleen 
focus forming virus (SFFV) proviral integration oncogene), namely Spi1 (also called 
PU.1), SpiB and SpiC (Table 5). ETS members are involved in the regulation of a 
number of key cellular processes, such as proliferation, differentiation, cell cycle, 
apoptosis and transformation [219]. Furthermore, they are critical for hematopoiesis 
and immune response [220]. 
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Table 5 
Top 25 enriched motifs on H3K27Ac common induced ChIPseq peaks as ranked by PSCAN. TFs 
known to recognize each motif are indicated. 
 
We next wanted to assess how many AP1 and ETS matrices were present in the 
H3K27Ac common induced peaks. By submitting the matrices that were most often 
represented at the top of the PSCAN ranks to Find individual motif occurrences 
(FIMO), we found that AP1 matrices were present on ~30-35% of H3K27Ac common 
induced peaks, while ETS members had varying yet higher degrees of occurrences 
(PU.1 matrices being the most present) (Table 6). Also in this case there was no 
TF Matrix ID P-value TF Matrix ID P-value
JDP2 TA0409_JDP2_full_dimer 1.37E-114 FosL2 HC_FOSL2_f1 3.64E-89
JDP2 TA0411_Jdp2_DBD_dimer 4.08E-112 JunD HC_JUND_f1 1.36E-83
JDP2 TA0407_JDP2_DBD_dimer 5.34E-108 Jun HC_JUN_f1 1.46E-83
NFE2 TA0422_NFE2_DBD_dimer 5.14E-103 SMRC1 HC_SMRC1_f1 2.22E-76
JunD HC_JUND_f1 1.94E-97 JunB HC_JUNB_f1 2.82E-73
BATF HC_BATF_si 1.96E-92 BATF HC_BATF_si 1.04E-66
Jun HC_JUN_f1 3.17E-91 JDP2 TA0409_JDP2_full_dimer 2.98E-64
FosL2 HC_FOSL2_f1 7.15E-91 JDP2 TA0407_JDP2_DBD_dimer 2.25E-63
JunB HC_JUNB_f1 5.34E-89 JDP2 TA0411_Jdp2_DBD_dimer 4.64E-62
SMRC1 HC_SMRC1_f1 1.66E-76 NFE2 TA0422_NFE2_DBD_dimer 2.78E-56
FosB HC_FOSB_f1 2.00E-74 Fos MA0099.1 Fos 1.54E-53
PU.1 HC_SPI1_si 7.54E-69 FosB HC_FOSB_f1 1.40E-50
Fos MA0099.1 Fos 1.43E-64 AP1 MA0099.2 AP1 5.48E-46
AP1 MA0099.2 AP1 5.56E-63 FosL1 HC_FOSL1_f2 3.72E-31
PU.1 TA0154_SPIB_DBD_monomer 2.01E-54 PU.1 ETS0027 h-SPI1 7.46E-20
PU.1 BU0058 Sfpi1_primary 2.72E-53 SPIB ETS0025 h-SPIB 1.95E-19
IRF8 GN_IRF8_TOP5000 2.95E-48 NFE2 HC_NFE2_f2 5.30E-19
SPIC TA0156_Spic_DBD_monomer 5.21E-48 SPIC ETS0026 h-SPIC 3.27E-18
SPIB HC_SPIB_f1 1.79E-45 BACH1 HC_BACH1_si 1.09E-17
PU.1 TA0153_SPI1_full_monomer 7.99E-41 PU.1 HC_SPI1_si 5.47E-17
FosL1 HC_FOSL1_f2 3.78E-40 MafK HC_MAFK_si 1.16E-16
PU.1 MA0080.2 SPI1 7.51E-37 ETS2 HC_ETS2_f1 1.14E-14
SPIC TA0155_SPIC_full_monomer 1.91E-36 ETV4 HC_ETV4_f1 2.15E-14
ELF5 HC_ELF5_f1 2.26E-35 NRF2 NRF2_NAR 1.85E-13
PU.1 ETS0027 h-SPI1 2.47E-35 Zfp281 BU0097 Zfp281_primary 1.43E-12
TF Matrix ID P-value TF Matrix ID P-value
JDP2 TA0409_JDP2_full_dimer 1.41E-43 FosL2 HC_FOSL2_f1 8.32E-103
JDP2 TA0407_JDP2_DBD_dimer 2.56E-43 JunD HC_JUND_f1 1.85E-99
JDP2 TA0411_Jdp2_DBD_dimer 2.11E-42 Jun HC_JUN_f1 9.33E-97
BATF HC_BATF_si 1.99E-39 SMRC1 HC_SMRC1_f1 3.18E-91
JunB HC_JUNB_f1 5.31E-38 JDP2 TA0409_JDP2_full_dimer 6.50E-80
JunD HC_JUND_f1 5.94E-38 JDP2 TA0407_JDP2_DBD_dimer 1.67E-77
NFE2 TA0422_NFE2_DBD_dimer 2.48E-37 JunB HC_JUNB_f1 1.26E-75
FosB HC_FOSB_f1 8.76E-36 Fos MA0099.1 Fos 1.88E-74
Jun HC_JUN_f1 1.90E-35 JDP2 TA0411_Jdp2_DBD_dimer 2.51E-73
FosL2 HC_FOSL2_f1 7.82E-31 BATF HC_BATF_si 2.93E-72
SMRC1 HC_SMRC1_f1 1.57E-30 NFE2 TA0422_NFE2_DBD_dimer 2.41E-70
Fos MA0099.1 Fos 3.59E-30 FosB HC_FOSB_f1 4.58E-67
AP1 MA0099.2 AP1 2.73E-27 PU.1 HC_SPI1_si 1.42E-56
TEF1 TA0317_TEAD1_full_monomer 8.60E-27 AP1 MA0099.2 AP1 2.28E-51
TEF5 TA0320_TEAD3_DBD_monomer 1.57E-22 FosL1 HC_FOSL1_f2 2.76E-40
PU.1 HC_SPI1_si 1.09E-21 PU.1 BU0058 Sfpi1_primary 6.83E-38
GATA2 HC_GATA2_si 5.56E-21 SPIB ETS0025 h-SPIB 1.88E-36
TEF3 TA0321_TEAD4_DBD_monomer 1.20E-20 PU.1 ETS0027 h-SPI1 1.53E-35
ELF5 MA0136.1 ELF5 3.15E-19 SPIC ETS0026 h-SPIC 7.73E-35
GATA3 TA0157_GATA3_DBD_monomer 1.13E-18 SPIB TA0154_SPIB_DBD_monomer 2.80E-29
GATA3 TA0158_GATA3_full_monomer 9.10E-18 IRF8 GN_IRF8_TOP5000 4.68E-25
GATA4 TA0159_GATA4_DBD_monomer 1.50E-17 SPIB HC_SPIB_f1 1.51E-22
GATA3 HC_GATA3_si 2.12E-17 ETV4 HC_ETV4_f1 1.69E-22
ELF5 HC_ELF5_f1 5.23E-17 SPIC TA0156_Spic_DBD_monomer 2.02E-21
GATA1 MA0035.2 Gata1 1.00E-16 NFE2 HC_NFE2_f2 3.77E-21
Inflamed Adenoma
Low grade HCC High grade HCC
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striking difference among different timepoint classes. 
 
 
Table 6 
Motifs occurrence analysis on H3K27Ac common induced ChIPseq peaks by FIMO. The number 
of occurrences, along with the relative percentage calculated on the total of the H3K27Ac 
common induced peaks for each stage, is shown. Motif occurrences with p-values smaller than 
10-4 have been considered. 
 
2. Genetic analyses1 
2.1 Single nucleotide variations analyses on Mdr2-KO HCCs 
The second part of this project was intended to screen for genetic modifications 
occurring during Mdr2-KO tumorigenesis. We aimed at identifying genetic alterations 
in tumors, in order to subsequently check which alteration is already appearing at 
earlier stages. 
                                                   
1 This part is product of collaboration with F. Iannelli, S. Sinha and F. Ciccarelli, European 
Institute of Oncology (IEO), Milan. 
 
N.#inflamed % N.#adenoma % N.#low#grade % N.#high#grade %
1608 100 2010 100 1408 100 2306 100
HC_JUN_f1/results/uniq.tab 616 38.3 775 38.6 459 32.6 897 38.9
HC_JUNB_f1/results/uniq.tab 653 40.6 800 39.8 474 33.7 914 39.6
HC_JUND_f1/results/uniq.tab 645 40.1 792 39.4 472 33.5 930 40.3
TA0407_JDP2_DBD_dimer/results/uniq.tab 428 26.6 482 24.0 278 19.7 535 23.2
TA0409_JDP2_full_dimer/results/uniq.tab 488 30.3 551 27.4 312 22.2 621 26.9
TA0411_Jdp2_DBD_dimer/results/uniq.tab 456 28.4 515 25.6 290 20.6 578 25.1
MA0099.1.Fos/results/uniq.tab 464 28.9 550 27.4 325 23.1 647 28.1
HC_FOSB_f1/results/uniq.tab 586 36.4 712 35.4 460 32.7 844 36.6
HC_FOSL1_f2/results/uniq.tab 638 39.7 805 40.0 511 36.3 943 40.9
HC_FOSL2_f1/results/uniq.tab 620 38.6 765 38.1 444 31.5 899 39.0
HC_NFE2_f2/results/uniq.tab 586 36.4 753 37.5 454 32.2 867 37.6
TA0422_NFE2_DBD_dimer/results/uniq.tab 473 29.4 531 26.4 304 21.6 619 26.8
HC_BATF_si/results/uniq.tab 630 39.2 790 39.3 467 33.2 887 38.5
MA0099.2.AP1/results/uniq.tab 565 35.1 706 35.1 420 29.8 819 35.5
HC_SPI1_si/results/uniq.tab 1112 69.2 1267 63.0 905 64.3 1562 67.7
BU0058.Sfpi1_primary/results/uniq.tab 690 42.9 676 33.6 486 34.5 904 39.2
MA0080.2.SPI1/results/uniq.tab 578 35.9 591 29.4 432 30.7 746 32.4
ETS0027.h/SPI1/results/uniq.tab 700 43.5 747 37.2 497 35.3 929 40.3
TA0153_SPI1_full_monomer/results/uniq.tab 713 44.3 662 32.9 513 36.4 888 38.5
HC_SPIB_f1/results/uniq.tab 766 47.6 760 37.8 565 40.1 974 42.2
ETS0025.h/SPIB/results/uniq.tab 667 41.5 751 37.4 499 35.4 929 40.3
TA0154_SPIB_DBD_monomer/results/uniq.tab 747 46.5 705 35.1 512 36.4 944 40.9
ETS0026.h/SPIC/results/uniq.tab 734 45.6 822 40.9 559 39.7 1012 43.9
TA0155_SPIC_full_monomer/results/uniq.tab 636 39.6 635 31.6 474 33.7 805 34.9
TA0156_Spic_DBD_monomer/results/uniq.tab 700 43.5 692 34.4 500 35.5 894 38.8
HC_ELF2_f1/results/uniq.tab 835 51.9 1000 49.8 637 45.2 1172 50.8
BU0012.Elf3_primary/results/uniq.tab 562 35.0 574 28.6 414 29.4 723 31.4
HC_ELF5_f1/results/uniq.tab 531 33.0 567 28.2 419 29.8 678 29.4
MA0136.1.ELF5/results/uniq.tab 582 36.2 630 31.3 461 32.7 760 33.0
HC_ETS2_f1/results/uniq.tab 723 45.0 931 46.3 600 42.6 1058 45.9
HC_ETV4_f1/results/uniq.tab 881 54.8 1027 51.1 686 48.7 1249 54.2
HC_FLI1_f1/results/uniq.tab 700 43.5 917 45.6 555 39.4 1069 46.4
Total#H3K27Ac#common#induced#peaks
AP1#
family
ETS#
family
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To map the somatic mutations acquired in Mdr2-KO lesions, target enrichment coupled 
to NGS was used. Nine nodules with varying percentages of HCC content, extracted 
from 10 to 16 months old individuals, were compared to a non-tumoral tissue (kidney) 
from one of these mice (Table 7). Mutational analysis was performed using a mouse 
all-exome probes array, targeting 21,543 genes (for a total 50,4 Mbp). We obtained 
22,4 Gb of raw reads per sample, with coverage ranging from 100 to 150x. After 
variant calling (see Materials and Metods), we identified a total of 118 SNVs, none of 
which was shared between any two tumors, and no indels (Tables 7), with less than 
0.4% of false positives. Sixty SNVs (51%) on a total of 60 genes were non-silent.  
Interestingly, Mdr2-KO lesions bore a lower number of somatic mutations per Mbp 
with respect to other solid tumors, including human HCC (Figure 9A). None of the 60 
non-silent mutations affected any ortholog of the 11 genes most frequently altered in 
human HCC , or any other gene known to be causally implicated in cancer  (data not 
shown). Furthermore, the length of genes associated to these mutations was 
significantly longer than for other mouse genes (Figure 9B), implying a higher 
statistical chance of random mutations in these genes. Additionally, 74% of mutated 
genes were either poorly or not expressed in mouse liver  (Figure 9C) indicating that 
they may be not functional in this tissue. Taken together, these observations suggest 
that these non-silent mutations do not have a driver role, and that therefore 
mutational instability is not the driving force in the development of liver cancer in 
Mdr2-KO mice. 
 
 
Table 7 
Somatic mutations detected by whole exome sequencing in Mdr2-KO lesions. 
 
Lesion ID Gender % adenoma %carcinoma Somatic Mutations Non-silent Mutations
51509/1 M 70 20 8 5
60400/2 F 30 40 8 3
218/1 M 20 50 5 2
52686/1 F 50 50 8 4
58853/3 M 0 60 20 8
60400/1 F 10 60 9 3
58163/3 M 20 70 17 6
58163/4 M 20 70 39 27
215/1 M 20 80 4 2
Total 118 60!
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Figure 9 
Spectrum of somatic mutations acquired in Mdr2-KO HCCs. 
(A) Frequency of non-silent somatic mutations in the nine mouse HCCs as compared to human 
leukemia [85, 221-224], HCC [151, 152, 154], and melanoma [225]. 
(B) Gene length comparison between mutated genes and rest of mouse genes. Gene length was 
calculated as the total nucleotides targeted by the Agilent SureSelect XT Mouse All Exon kit. 
Differences in length distributions were assessed using Wilcoxon test. 
(C) Expression levels of the mutated genes in normal liver [212] in the two replicates (Exp.1 
and Exp.2) and the average expression over the replicates (Union). Normalized gene expression 
(Nexp) was calculated as the gene expression level over the median expression of all genes in 
liver. Values above and below zero indicate gene expression higher and lower than the median. 
-1 indicates no expression in liver. 
 
2.2 Copy number variations assessment on Mdr2-KO HCCs 
We then examined the incidence of copy number variations (CNVs) from the targeted 
sequencing data of the 9 Mdr2-KO exomes screened for point mutations, using a novel 
method based on the comparison of the normalized gene coverage between tumor 
and its normal counterpart (see Materials and Methods). We observed that 2,430 
(~11%) of the analyzed genes displayed CNV in at least 1 sample, and that gene 
amplifications were the overwhelming majority (2,427) of these alterations (Table 8). 
Validation via TaqMan copy number assay of 10 predicted gene amplifications 
estimated 93% specificity, 85% accuracy, and 70% sensitivity of our CNV detection 
A B 
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method (data not shown). This evidence suggested that CNVs represent a common 
genetic alteration in this model. 
To further assess this possibility, we performed whole genome sequencing of two 
HCCs extracted from two different mice (one of them belonging to the set previously 
analysed by whole exome sequencing), using the corresponding kidney as matched 
normal control. Again, we observed a predominance of amplifications over deletions, 
with a total of 1,074 amplified and 117 deleted genes in the two genomes (Table 8). 
The vast majority of amplified genes detected in the whole exome (85%) were also 
found in the whole genome, confirming the reliability of the method. Notably, the 
percentage of amplified genes positively correlates with the HCC content in these 
lesions (Figure 10), indicating that CNVs occur preferentially at late stages of HCC 
development. 
Overall, CNV analysis showed that Mdr2-KO HCCs frequently develop CNVs, in 
particular gene amplifications. CNVs mostly occur at late tumorigenic stages, thus 
suggesting a possible driver role in tumor progression.  
 
 
Table 8 
Copy number variations detected by whole exome and whole genome sequencing in Mdr2-KO 
lesions. In total, 2,427 amplified and 4 deleted genes were detected in the nine whole exomes, 
and 1,074 amplified and 117 deleted genes were found in the two whole genomes. * TaqMan 
copy number assay assessed high number of false negative for this sample, suggesting an 
overall underestimation of gene amplifications. 
 
Lesion ID Gender % adenoma %carcinoma Targeted regions Amplified genes Deleted genes Total CNVs
51509/1 M 70 20 59 0 59
60400/2 F 30 40 113 0 113
218/1 M 20 50 298 1 299
52686/1 F 50 50 15 2 17
58853/3 M 0 60 631 0 631
60400/1 F 10 60 455 0 455
58163/3 M 20 70 333 1 334
58163/4 M 20 70 625 0 625
215/1 M 20 80 562 0 562
60400/1 F 10 60 529 2 531
218/3 M 10 70 652 115 767
Total 4,272 121 4,393
Whole exome
Whole genome
!
*
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Figure 10 
Number of genes amplified in 10 Mdr2-KO tumors as a function of the corresponding HCC 
content. The plot is based on the 10 mouse tumors that underwent whole exome and whole 
genome sequencing. Correlation was assessed using Pearson correlation test. 
 
2.3 Analysis of recurrently altered genes in Mdr2-KO HCCs 
In order to identify putative cancer driver genes, we focused on the 69 genes 
amplified in at least 50% of the sequenced HCC exomes (~2% of all altered genes, 
Figure 11A). Around 67% of them laid on chromosome 8, accounting for almost 4% 
of the genes on this chromosome (Figure 11B), implying that chromosome 8 is 
recurrently rearranged in Mdr2-KO liver cancer.  
Among the top scoring genes, we found that Map2k7 was amplified in the 4 samples 
(out of 9) having the highest HCC content (data not shown). Map2k7 encodes for 
JNKK2/MKK7, an upstream activator of the c-Jun NH(2)-terminal kinases (JNKs) 
[226], which are mainly triggered by pro-inflammatory cytokines and environmental 
stress [227]. Since JNK pathway deregulation has already been associated with liver 
cancer [228, 229], Map2k7 seemed a good candidate for further investigation. We 
screened 35 additional tumors from 16 distinct individuals by TaqMan copy number 
assay and found that Map2k7 was amplified in 14/49 Mdr2-KO nodules (29%, Table 
S7), a frequency much higher than expected by chance (p=6x10-04, binomial test). 
Seven of the 12 nodules composed of ≥40% HCC (58%) showed Map2k7 amplification 
(Table S7), a fraction again significantly higher than expected by chance (p=9x10-05, 
binomial test), indicating that Map2k7 amplification occurred more frequently in 
lesions with high HCC content. 
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Figure 11 
Recurrent gene amplifications in Mdr2-KO HCCs. 
(A) All amplified (green) and deleted (red) genes in 10 tumor exomes, grouped according to the 
number of samples where they were altered. No gene was modified in more than seven tumors. 
(B) Fraction of recurrently amplified genes in each chromosome, measured as the number of 
amplified genes over the total number of targeted genes in that chromosome. 
 
In order to understand whether Map2k7 amplification impacts on its steady state 
mRNA levels, we measured Map2k7 expression on the tumoral samples screened for 
CNVs. In particular, we compared MKK7 mRNA levels of 9 nodules that were found to 
bear map2k7 amplifications with that of 7 lesions with no CNV for map2k7, 9 age-
matched inflamed livers and 9 age-matched WT livers (Figure 12). MKK7 expression 
in the amplified samples was higher with respect to all other sets of samples. An 
increase in MKK7 expression was also detected in samples with normal map2k7 copy 
number with respect to inflamed and WT samples. This finding suggests that an 
upregulation in the expression of JNK pathway components, due to either an increase 
in gene copy number or increased transcription, may represent a selected event in 
HCC development in Mdr2-KO mice. 
 
 
A B 
 73 
 
Figure 12 
MKK7 expression analysis on Mdr2-KO HCC nodules with or without Map2k7 amplification vs 
Mdr2-KO inflamed livers and Mdr2-WT livers. Number of screened samples are indicated in 
brackets. Values are expressed as percentage of fold MKK7 expression normalized on 
expression of nucleolin as a control gene. Differences between distributions were assessed using 
Wilcoxon test. 
 
Indeed we found that all but one tumors had modifications in at least one primary JNK 
interactor (defined as a protein that engages direct physical interactions with the core 
component of the JNK pathway, Figure 13). We measured the distance of the 
proteins encoded by all altered genes in all tumors from any component of the JNK 
pathway in the human protein-protein interaction network and observed that they are 
closer to the JNK pathway than expected by chance (p = 2x10-04, Wilcoxon test). This 
indicates that the alteration of other JNK pathway components in addition to Map2k7 
is a pervasive feature of Mdr2-KO HCC. 
Collectively, these data show that gene amplifications in in Mdr2-KO tumors 
preferentially hit specific genes, most notably Map2k7. These gene alterations suggest 
that the deregulation of the JNK pathway that may have a driver role in liver tumor 
progression.    
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Figure 13 
Network of JNK protein-protein interactions. Shown are 14 primary interactors of JNK and two 
secondary interactors that are recurrently mutated in Mdr2-KO tumors. The number of tumors 
where the gene was amplified (green) or mutated (purple) are reported in brackets. 
 
2.4 Effects of inhibition of the JNK pathway on Mdr2-KO nodules 
In order to understand whether Map2k7 amplification was biologically relevant to HCC 
progression, we treated 13 to 14 months old Mdr2-KO mice with SP600125, a 
synthetic polyaromatic inhibitor of the JNK kinases [230]. After three weeks of 
treatment, mice were sacrificed and the tumors from the two cohorts were compared 
in terms of nodule number, size, histological composition, and tumor content.  
Although inhibition of JNK did not have an effect on the number of HCC nodules 
eventually detected, it had an obvious effect on tumor size. Indeed, mice treated with 
SP600125 did not develop any tumors larger than 20 mm, in contrast to about 20% of 
mice treated with vehicle (Figure 14A), despite a similar proportion of nodules with 
Map2k7 amplification in the two groups (Table S8). When considering the histological 
composition of the lesions, nodules bigger than 10 mm in treated mice showed 
significantly higher proportion of adenoma and lower proportion of carcinoma as 
compared to untreated mice (Figure 14B). No difference was detectable in the 
histological composition of smaller lesions. Similarly, by comparing the tumor burden 
per mouse in the two cohorts, treated mice showed an overall significant depletion in 
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HCC, while purely adenomatous nodules were over-represented (Figure 14C).  
In summary, these results indicate JNK pathway activation as a driving requisite for 
Mrd2-KO cancer progression, and in particular for the adenoma-to-carcinoma 
transition in Mrd2-KO tumors. These data are consistent with the frequent emergence 
of Map2k7 amplification in high grade HCCs (Figure 10). 
 
 
 
Figure 14 
Effects of JNK inhibition on Mdr2-KO liver nodules. Analyzed nodules or mice in the two groups 
are reported in brackets. All differences were assessed using Fisher's exact test. See also Table 
S8. 
(A) Size differences among treated and untreated nodules.  
(B) Histological composition of treated and untreated nodules. Nodules in the two cohorts of 
mice were divided into two groups according to the size (reported on top).   
 
2.5 Point mutation and CNV analyses on human PFIC-related HCC 
The data presented insofar showed several features that distinguish HCC arising in 
Mdr2-KO mice from human HCC. First, we reported that the frequency of non-silent 
somatic mutations in Mdr2-KO HCCs is much lower than the frequency that has been 
measured in human liver cancer [14, 150-152, 154, 231], which is nonetheless 
comparable to that of other solid tumors (Figure 9A). Furthermore, none of the 
recurrently mutated genes in human HCCs [209] was found mutated in the mouse 
lesions that we screened. Finally, we observed that Mdr2-KO tumors are far more 
A B C 
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prone to accumulate gene amplifications that deletions, which is the opposite of what 
found in human liver cancer [14, 150, 152, 231] (Table 8). These peculiar differences 
might be attributed to species-specific traits, implying that this mouse model of HCC 
does not recapitulate the genetics of the human disease. Nevertheless, the majority of 
patients analysed so far developed liver cancer upon exposition to virus infection or 
other risk factors (e.g. alcohol), which have distinct and specific impact on the 
acquisition of genomic alterations [209]. Therefore, as Mdr2-KO HCC is induced by 
inflammation due to cholestasis and independently from external factors, a possibility 
is that the observed differences might be due to different disease pathogenesis rather 
than to inter-species diversity.  
We therefore sequenced the whole exome of HCCs from six individuals affected by 
Progressive Familial Intrahepatic Cholestasis (PFIC, Table S9). As mentioned, 
different PFIC forms are recognized based on the impaired liver transporter genes, and 
PFIC type 2, in which mutations of the ABCB11 gene lead to bile salt export deficiency, 
is associated with early onset pediatric hepatocellular carcinoma [232].  
In the exomes of all six human tumors, we detected a total of 44 somatic mutations, 
none of them being shared between the two patients, and 8 indels (Table 9). Of these 
modifications, 15 mutations and no indels were non-silent (Table 9). However, none 
of them was a known driver gene in HCC or in other human cancers [209, 210]. 
Moreover, as in the case of Mdr2-KO, most of these genes were poorly or not 
expressed in human normal liver [212], thus indicating that all 15 mutations were 
likely passenger (data not shown).  
To investigate whether the massive copy number alterations observed in Mdr2-KO 
HCCs also occur in PFIC human HCC, we screened for somatic CNVs in seven PFIC-
related HCCs, including all lesions screened for point mutations and one additional 
sample. We detected a total of 18,428 genes that underwent amplifications and 3,628 
genes that underwent deletions, with an overwhelming predominance of copy number 
gains over losses, similar to what observed in the mouse tumors (Table 10). Although 
amplifications were generally widespread along the entire genome, chromosome 8, 19 
and 20 were almost completely amplified in the majority of lesions. Indeed, 
amplification of chromosome 19 was confirmed in sample 23836 by fluorescence in 
 77 
situ hybridization (FISH) with probes located on both chromosomal arms (Figure 15). 
Interestingly, human MAP2K7 is located on chromosome 19 and it was therefore 
amplified in the liver of this patient. Actually, MAP2K7 was found amplified in 5 lesions 
out of 7 (Table 11). 
Altogether, these findings suggest a similar genetic landscape for purely inflammatory 
human and murine HCCs. 
 
 
Table 9 
Somatic mutations in human PFIC-related liver cancers. None of the identified indels introduced 
a frameshift (i.e. was non-silent). 
 
 
Table 10 
Copy number alterations in human PFIC-related liver cancers.  
 
 
Lesion ID Gender % carcinoma Somatic Mutations Non-silent Mutations Somatic Indels
175 M 90% 7 3 0
7860 F 90% 5 2 0
23836 M 90% 5 1 0
HB4R F 70% 25 9 7
1790 M 60% 1 0 0
2896 F 50% 1 0 1
Total 44 15 8-
Lesion ID Gender % carcinoma Screening Amplified genes Deleted genes Total CNVs
175 M 90% WES + CNV 10,688 1 10,689
7860 F 90% WES + CNV 13,594 1,248 14,842
23836 M 90% WES + CNV 12,450 19 12,469
HB4R F 70% WES + CNV 5,598 2,575 8,173
1790 M 60% WES + CNV 8,601 0 8,601
2896 F 50% WES + CNV 9,687 244 9,931
MB M 40% CNV 3,801 258 4,059
Total 18,428 3,628 22,056-
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Figure 15 
Amplification of chromosome 19 in patient 23836 as detected by FISH. Shown are four 
representative hepatocytes nuclei (blue, DAPI staining) from the paraffin-embedded tumor 
sample. Probes on chr19p13 (green) and on chr19q13 (orange) were used and nuclei in a-b-c 
show additional copies of chromosome 19, while the nucleus in d has only two. 
 
 
Table 11 
Fraction of PFIC tumors with Map2k7 (MMK7) and Mapk8 (JNK) copy number alterations. For 
each patient the number of gene copies is indicated. 
 
 
 
 
 
 
 
 
175 7860 23836 HB4R 1790 2896 MB
MAP2K7 3 7 4 3 2 3 2 5 0
MAPK8 2 4 3 3 3 3 2 5 0
Samples with 
deletionGene Name
Copy Numbers Samples with 
amplification
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DISCUSSION 
 
1. Mdr2-KO HCC is epigenetically characterized by a hepatocyte-
specific inflammatory signature 
The first part of this project was focused on the elucidation of epigenetic changes 
occurring in the context of a chronic inflammation-driven tumorigenic process. 
Specifically, we performed the epigenetic profiling of a panel of histone marks by 
ChIPseq on liver samples from Mdr2-KO mice, as a model of spontaneous 
inflammation-derived liver cancer.  
We were primarily interested in the identification of TFs activated during the 
progression to cancer, in order to infer which molecular players are required at the 
chromatin level for tumor origin and development. Therefore, by applying a “reverse 
epigenetics” approach, we profiled H3K27Ac, a mark of active regions, to unveil TFs 
whose recruitment would be critical at each pathologic step (namely, chronic 
inflammation, adenoma, low grade HCC and high grade HCC). 
We have shown that ~1,400 to 2,300 regions become hyperacetylated (with respect 
to the WT counterpart) in all samples of a given disease stage, and that gain in 
acetylation generally corresponds to a gain of H3K4me1 mark in inflamed and low 
grade HCC tissues.  
Gene ontology analyses of these regions compared to the WTs suggested the 
acquisition of an inflammatory signature during the chronic inflammation stadium, 
possibly in response to the exposition to cytokines and other inflammatory mediators. 
This is in agreement with previous reports showing that hepatocytes exposed to 
activated macrophages in vitro display an up-regulation of pathways (such as the IFNγ 
and the TNF receptor 2 pathways) associated to inflammatory responses [233]. We 
showed that this inflammatory signature is retained throughout the tumorigenic 
process until the latest cancer stage. Interestingly, the absence of inflammatory 
infiltrates inside the nodular lesions implies that this signature is specific of 
hepatocytes and that, once triggered, its retention is independent of an inflammatory 
microenvironment. 
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The importance of the crosstalk between non-parenchymal cells and hepatocytes, both 
for the establishment and propagation of acute and chronic inflammation, is well 
known [234]. Nevertheless, to what extent hepatocytes per se contribute to 
inflammation, independently of stimuli deriving from other cell populations, is still 
unclear. They have been found to express mRNA for all the types of Toll-like receptors 
(TLRs), crucial in the recognition of pathogen-associated molecular patterns and for 
the anti-microbial response, as well as their adaptor molecules MyD88 and MD2 [235]. 
In keeping, hepatocytes have been shown to respond to lipopolysaccharide and other 
TLR4 ligands, although the degree of response is still matter of debate [236-238]. 
Moreover, stimultation of TLR3 with polyI:C caused the activation of type 1 interferon 
in hepatocytes [239]. Few studies on cell lines also showed the expression of specific 
cytokines and chemokines in stimulated hepatocytes [240-242]. Our results might 
point to an active involvement of hepatocytes in contributing to the inflammatory 
environment. 
At every disease stage, we observed that DNA motifs recognized by AP1 and ETS 
family members were enriched in common H3K27Ac induced peaks.  
The AP1 family entails a group of structurally and functionally related proteins 
belonging to different subfamilies, the main ones being the Jun, Fos, ATF and JDP 
subfamilies [217]. In common H3K27Ac-induced regions, we found enrichment of 
consensus sequences for all the principal AP1 subfamilies. AP1 members homo- and 
heterodimerize, depending on cell type-specific concentrations of each family member, 
and giving rise to different species of AP1 transcription factors. Upon dimerization, 
these TFs are able to recognize TPA (tetradecanoylphorbol acetate)-DNA responsive 
elements (TREs, consensus sequence 5′ -TGAG/CTCA- 3′) [218]. AP1 TFs activity is 
dependent on a broad range of stimuli, including cytokines, growth factors, infection, 
stress signaling and oncogenic factors, and is influencing key cell functions such as 
proliferation and apoptosis. AP1 activity is further controlled by upstream kinases, in 
particular by JNK [218]. 
The ETS family has been implicated in a number of crucial cell processes, from 
proliferation and differentiation to apoptosis and senescence [219]. Moreover, one of 
the best studied role of ETS TFs is the regulation of hematopoiesis, and some ETS 
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proteins are also involved in vasculogenesis, neuronal development and immunity 
[220, 243]. ETS is a large and variegated group of TFs, with approximately 29 
members differently expressed according to cell type. The most frequently retrieved 
ETS matrices were associated to the SPI subfamily, and in particular to PU.1. 
Nevertheless, none of the SPI members are known to be expressed in liver under 
physiological conditions [212]. It would be interesting to measure the expression 
levels of PU.1, SpiB and SpiC in Mdr2-KO tumoral samples, in order to understand 
whether cancer development could cause ectoptic SPI members expression. 
Intriguingly, several genome-wide association studies recently found several intronic 
SNPs on SPIB locus to be a risk factor for primary biliary cirrhosis [244-246]. 
Moreover, further analyses will be necessary to estimate to what extent are combined 
AP1 and ETS motifs present in common hyperacetylated regions. In fact, one 
possibility is that regions acquiring H3K27Ac and becoming “open” would be bound by 
AP1 members only, despite the concurrent presence of an ETS motif. On the other 
hand we could speculate that, given the high degree of similarity between matrices 
associated to SPI members and other ETS subfamilies, and the high percentages of 
occurrence of other ETS TFs matrices reported by the FIMO analysis (Table 6), the 
ETS sites present in the common H3K27Ac induced regions are not bound by SPI TFs, 
but rather by other ETS proteins. 
It will be however interesting to evaluate the expression levels of both AP1 and ETS 
family members during the progression to cancer, in order to select for relevant TF 
candidates for genome wide occupancy studies. For this reason, and in order to 
compare results with expression profiles, we are planning to perform RNAseq analyses 
on the same samples that have been used for ChIPseq. 
By focusing on H3K27Ac mark, we chose to search for regions that become active 
during the disease progression. Nevertheless, important information can be obtained 
also from regions inactivated during the tumorigenic process. Therefore, future work 
will be focusing on profiling of repressive chromatin marks (i.e. H3K9me3, K3K27Ac).  
Gene ontology and motif enrichment analyses failed to cluster samples according to 
the disease stage. This was due to the fact that the activation of inflammatory 
components, and the suggested involvement of AP1 TF family, was a pervasive 
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feature of all the Mdr2-KO pathologic steps starting from the development of 
inflammation. In order to reveal epigenetic changes specifically occurring upon cancer 
onset, it will be critical to perform analyses by keeping the inflamed samples (rather 
that the WT samples) as reference.  
Finally, a crucial level of information to be added in order to have a more complete 
picture of epigenetic changes occurring along Mdr2-KO tumorigenesis would be 
constituted by DNA methylation. We are planning to obtain single base resolution, 
genome wide methylation profiles of the same samples that underwent ChIPseq 
analyses, in order to delineate the interplay between the two types of modifications. 
 
2. Mdr2-KO mice develop late stage HCC-associated gene 
amplifications 
The second part of the present study was aimed at assessing the impact of 
inflammation on the origin of genetic alterations and the consequent emergence of 
cancer. In particular, we screened for the presence of point mutations and copy 
number variations in hepatocellular carcinoma lesions from Mdr2-KO mice. What 
emerged is that CNVs, and particularly gene amplifications, is the most common 
mutational event in this system. Previous evidences obtained in our lab (data not 
shown) indicated that no genetic modifications are present at earlier pre-tumoral 
stages (chronic inflamed tissue, dysplastic liver). This implies that mechanisms other 
than genetic are the driving cause of tumor origin. By integration with the epigenetic 
data, it would be therefore interesting to understand whether epigenetic modifications, 
by regulating chromosome packing and stability, are implied in this scenario. 
Results obtained by massive parallel sequencing and biological validations unveiled a 
key role for Map2k7 (MKK7) in particular, and for the JNK pathway more in general, in 
inflammation-derived HCC. MKK7 is known to be essential for pro-inflammatory 
cytokines to stimulate JNK activity [226]. Furthermore, Map2k7 is expressed in 
embryonic liver, where it is important to drive proliferation by upregulating the levels 
of the Cdc2 kinase [247]. In addition, liver-specific deletion of Mapk14, a negative 
regulator of Map2k7, leads to JNK hyperactivation and higher tumor development 
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[248]. MKK7 oncogenic potential is nevertheless still controversial, as it was recently 
described to play a tumor-suppressive action in murine lung and mammary cancer 
[249].  
However, the implication of JNK in liver cancer is well known. Lack of c-Jun 
dramatically reduces liver carcinogenesis in DEN-induced mouse HCC model [250], 
and Jnk-/- mice exhibit reduced liver tumors [251]. Proliferation of human and murine 
HCC was shown to require JNK1-dependent p21 downregulation [252]. Importantly, 
70% of human HCC tissues have been found to be positive for phospho-JNK 
immunostaining [253]. Chronic activation of TGF-β activated kinase 1 (TAK1) and JNK 
due to disruption of cylindromatosis tumor suppressor (Cyld) gene was recently 
described to cause massive hepatocyte death accompanied by compensatory 
hepatocyte proliferation, which leads to development of HCC [228]. Despite all these 
indications underlining the importance of JNK in liver cancer, whether JNK pathway 
activation is occurring in hepatocytes rather than in other non-parenchymal liver cells 
is still matter of debate. Das and colleagues suggested that JNK seems to promote 
HCC formation in non-parenchymal cells by increasing the production of pro-
inflammatory cytokines, while playing an opposite role in hepatocytes, where 
combined deficiency of Jnk1 and 2 is linked to increased tumor size in DEN- treated 
mice [229].  
Nevertheless, our work contributes to demonstrating an alteration of JNK pathway 
(and of MKK7 in particular) specifically into hepatocytes, which does not exclude a 
parallel misregulation inside other types of liver cells. Furthermore, we show that 
deregulation of JNK pathway in HCC is due to a genetic alteration. In particular, we 
saw that JNK amplifications generally occur at late stage of HCC development, 
therefore the deregulation of this pathway is likely to favour cancer progression rather 
than tumor initiation. Amplification of Map2k7, as well as recurrent alteration of JNK 
pathway components, has not been reported in any WES or WGS study on human 
HCC [14, 150-152, 154, 231]. Interestingly, and relevant to the first part of this 
study, JNK is one of the main upstream activators of AP1 family components. 
In order to understand whether the pattern of modifications depicted in this work is 
directly due to the inflammatory context and it is not simply specific to the mouse 
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model (which, despite approximating human HCC pathogenesis, surely constitutes a 
different background), we were interested in testing whether the same genetic lesions 
were occurring in human HCC patients. In an attempt to chose an exclusively 
inflammation-driven cancer, and given the importance of the disease etiology, we 
validated our findings on samples deriving from PFIC patients. Importantly, we found 
that these patients display a genetic alteration pattern very similar to the one 
envisaged for Mdr2-KO mice, with no candidate driver mutations, very low mutation 
rates, and high CNV frequency with predominance of CN amplifications. Taken 
together, these evidences demonstrate that Mdr2-KO mice closely recapitulate the 
genomic lesions occurring in PFIC patients, and confirm that HCC deriving from a 
purely inflammatory background has a peculiar genomic landscape that markedly 
differs from viral HCC.  
In conclusion, this part shows that inflammation per se promotes the generation of a 
distinctive genomic signature in the liver, which is sharply different from those 
originating from virus- and chemical-induced inflammation. In particular, 
inflammation-derived HCC does not display genomic alterations in the earliest 
tumorigenic steps, and is accompanied by recurrent gene amplifications (particularly 
on Map2k7 and other JNK pathway members) during tumor progression.  
 
3. Working model and future perspectives 
With this work, we aimed at detecting mutations and epigenetic modifications induced 
by chronic inflammation at each stage of tumor origin and development. We have 
shown that, during a chronic inflammation-driven tumorigenic process, an activation 
of JNK-AP1 components is triggered early upon tissue inflammation, and is persistence 
throughout disease progression. Upon formation of nodular lesions, despite 
segregation from the surrounding inflammatory milieu, an epigenetic inflammatory 
signature acquired by hepatocytes is maintained, and at the latest stages of tumor 
development this correlates to genetic alteration events that lead to JNK pathway 
amplification (Figure 16). 
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Figure 16 
Working model. 
 
Future work will be necessary to corroborate this working model. In particular, in 
order to definitely clarify whether the JNK pathway is functional to tumorigenesis, an 
interesting possibility would be to inhibit JNK or Jun in Mdr2-KO mice specifically in 
hepatocytes. It would be possible to cross Mdr2-KO mice with c-junf/f mice [254], in 
order to genetically knock out the JNK pathway. Nevertheless, this could influence the 
peculiar genetic landscape that drives tumorigenesis in the Mdr2-KO model. Another 
possibility would be to abrogate JNK pathway via RNA interference (RNAi), by 
adenoviral infection of shRNA (short hairpin RNA) or by hydrodynamic pump injection 
of naked siRNA (small interfering RNA) [255, 256]. 
Nevertheless, this project primarily represents an effort toward producing an 
integrated analysis of the nuclear changes occurring in a murine model of cancer, by 
the generation of genome-wide, multi-stage datasets for multiple levels of complexity 
(genomic, epigenomic and, in future, transcriptomic). The long-term goal in this 
process, once more exhaustive information from each level of complexity will be 
achieved, will be to funnel these variegated datasets into an integrated systems-level 
model, in order to determine the temporal relationship and interplay of modifications 
in different compartments. This will help in shedding light on the complex system of 
interactions between genomic and epigenomic machineries and how alterations in this 
crosstalk can lead to disease. 
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SUPPLEMENTARY FIGURES AND TABLES 
 
 
 
Figure S 1 
Hematoxylin/eosin histological analysis of livers from Mdr2-KO and Mdr2-WT mice. At 8 weeks 
ductular proliferation is visible despite a general architecture conservation. Hyperproliferation 
and severe architectural dysplasia are observed at 4 months, which leads to development of 
incapsulated adenoma between 9 and 12 months and, subsequently, to end-stage tissue 
disruption and HCC. 
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Figure S 2 
Immunohistochemistry on livers from Mdr2-KO and Mdr2-WT mice (8 weeks and 4 months old, 
same individuals as in Figure S1). Liver slices have been stained with a biotinylated anti-CD3 
antibody to visualize inflammatory infiltrate in the periportal parenchymal tissue of Mdr2-KO 
mice. 
 
 
 
Figure S 3 
Measurement of alanine aminotransferase (ALT) plasma levels on Mdr2-KO and Mdr2-WT mice 
(8 weeks, 4 months and 10 months old). 
WT
(3 months)
KO
(8 weeks)
KO
(4 months)
10x 20x 40x
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Figure S 4 
FACS analysis to evaluate purity and viability of a hepatocyte preparation obtained by liver 
perfusion. Due to the lack of a reliable membrane marker for hepatocytes, cells have been 
stained for CD11b and CD31, to mark Kupffer and endothelial cells, respectively (the two most 
represented populations in liver after hepatocytes). As reported, cell contaminants in our 
preparations is very low (0,0015% for Kupffer and 1,297% for endothelial cells). Viability is 
evaluated with propidium iodide, and the percentage of dead cells (between 34,22% and 
43,17%) is similar to the percentage observed by Trypan blue inclusion. 
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Figure S 5 
Preliminary H3K4me1 ChIPseq to evaluate possible differences due to the hepatocytes or tissue 
preparation protocol. In order to exclude data variability due to differences introduced by the 
extraction of hepatocytes by liver perfusion with respect to the direct liver excision and 
homogenization, livers from two 8 weeks old Mdr2-WT animals have been processed with each 
protocol. A third condition has been introduced, by eliminating the final centrifugation step from 
the perfusion protocol, which allows to separate hepatocytes from non-parenchymal cells, but at 
the same time could modify chromatin (as it is performed prior to cell fixation). A representative 
snapshot of the ChIPseq tracks is shown (on top), along with the tracks correlation values (at 
the bottom). The low differences observed among different procedures has been confirmed also 
by CAGE transcriptome analysis (K. Hashimoto, P. Carninci, personal communication).  
 
 
1 2 1 2 1 2
1 1 0.76 0.74 0.74 0.72 0.68
2 1 0.72 0.72 0.72 0.63
1 1 0.75 0.73 0.71
2 1 0.72 0.71
1 1 0.67
2 1
perfusion with 
centrifugations
perfusion without 
centrifugations
no perfusion
perfusion with 
centrifugations
perfusion without 
centrifugations no perfusion
 91 
 
Table S 1 
Sequencing throughput for ChIPseqs on Mdr2-WT and Mdr2-KO liver samples. Indicated are the 
total number of raw reads, the number of reads aligned to the genome, and the number of 
reads retained after MACS filtering. 
Stage Sample N. total reads N. mappable reads N. reads after MACS filtering
1 27,770,349 23,259,196 21,411,218
2 28,874,387 24,190,080 23,048,350
3 18,323,808 12,369,490 9,931,612
4 22,793,087 19,972,486 18,723,015
Pool 28,606,217 24,286,097 24,134,260
1 26,967,372 24,201,794 23,103,068
2 39,897,199 33,984,279 31,069,231
3 34,343,371 29,210,045 28,566,775
4 23,233,563 19,913,343 19,140,602
1 40,739,350 37,053,973 37,053,973
2 38,107,393 33,730,908 32,491,297
3 33,684,721 30,579,301 29,962,831
4 24,536,935 22,106,399 21,473,683
1 43,696,757 39,030,007 32,091,423
2 34,657,078 30,312,762 29,049,282
3 25,785,873 22,117,795 21,616,900
4 26,779,208 19,078,268 15,015,739
5 22,427,820 19,787,898 19,114,527
1 40,592,567 36,349,089 34,719,289
2 7,953,798 7,066,028 6,299,431
3 38,810,413 34,587,358 33,461,884
Pool 17,395,259 15,364,786 15,192,535
1 70,979,664 56,934,985 53,380,695
2 35,471,038 28,557,650 28,054,184
3 27,263,257 17,153,262 11,619,052
4 61,380,255 46,655,207 32,478,331
Pool 69,565,992 52,255,783 51,893,368
1 36,411,874 31,607,891 30,395,234
2 46,346,414 37,197,040 35,287,692
3 89,779,177 70,012,477 66,133,061
4 53,262,889 44,190,787 42,925,259
1 53,875,025 47,387,026 42,386,451
2 26,166,831 21,962,891 21,501,428
3 67,355,899 56,348,222 55,296,406
4 40,264,844 20,789,839 13,703,868
5 38,729,729 33,887,751 31,864,028
1 18,278,734 8,965,391 3,451,238
2 39,155,420 27,431,430 19,979,750
3 14,042,479 7,629,898 3,779,985
4 32,712,484 23,799,122 14,054,666
Pool 27,464,787 19,650,752 18,002,143
1 40,343,074 27,026,764 21,850,997
2 34,572,032 21,386,508 18,736,487
3 33,379,450 17,409,400 16,076,518
4 32,203,587 18,583,977 17,250,866
1 29,491,423 20,107,086 15,271,835
2 21,278,833 12,571,038 11,658,429
3 21,568,234 13,821,282 12,477,976
4 20,525,425 13,758,851 10,584,222
5 25,251,303 15,811,058 13,736,223
H3K4me1
H3K4me3
WT
Inflamed
Low grade 
HCC
WT
Inflamed
Low grade 
HCC
High grade 
HCC
Low grade 
HCC
Adenoma
Inflamed
WT
H3K27Ac
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Figure S 6 
Number of peaks for Mdr2-KO H3K4me1 ChIPseq samples. Numbers of the WT samples (in 
blue) are reported at the bottom of each bar. Dashed black lines indicate the number of 
common peaks of each sample when compared to each of the WT samples, while dashed blue 
lines indicate common peaks among all samples compared to all WTs. 
 
 
Figure S 7 
Number of peaks for Mdr2-KO H3K4me3 ChIPseq samples. Numbers of the WT samples (in 
blue) are reported at the bottom of each bar. Dashed black lines indicate the number of 
common peaks of each sample when compared to each of the WT samples, while dashed blue 
lines indicate common peaks among all samples compared to all WTs. 
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Table S 2 
Top 20 “Biological Processes” terms of GREAT analysis on H3K27Ac common ChIPseq peaks 
from inflamed samples. 
 
 
 
Table S 3 
Top 20 “Biological Processes” terms of GREAT analysis on H3K27Ac common ChIPseq peaks 
from adenoma samples. 
 
# Term Name  Binom Rank  Binom Raw P-Value   Binom FDR Q-Value  
immune system process 1 5.25E-47 4.50E-43
regulation of immune system process 2 5.16E-45 2.21E-41
positive regulation of immune system process 3 5.36E-32 1.53E-28
response to wounding 5 5.10E-29 8.75E-26
regulation of immune response 8 7.33E-27 7.87E-24
cell activation 13 2.63E-22 1.74E-19
response to biotic stimulus 14 4.08E-22 2.50E-19
response to other organism 16 1.27E-21 6.80E-19
regulation of response to stress 17 1.36E-21 6.89E-19
defense response 18 7.81E-21 3.72E-18
leukocyte chemotaxis 19 1.62E-20 7.33E-18
phagocytosis 20 1.79E-20 7.70E-18
endocytosis 21 2.38E-20 9.72E-18
immune response 22 2.56E-20 9.99E-18
regulation of cell activation 24 3.39E-20 1.21E-17
leukocyte activation 25 4.73E-20 1.62E-17
leukocyte migration 26 6.95E-20 2.29E-17
wound healing 27 1.81E-19 5.76E-17
regulation of myeloid leukocyte mediated immunity 28 2.48E-19 7.59E-17
cellular membrane organization 29 3.93E-19 1.16E-16
membrane organization 30 4.10E-19 1.17E-16
regulation of leukocyte activation 31 7.02E-19 1.94E-16
regulation of leukocyte degranulation 33 3.97E-18 1.03E-15
hemopoietic or lymphoid organ development 34 9.94E-18 2.51E-15
regulation of cytokine production 35 1.50E-17 3.67E-15
actin filament-based process 37 4.15E-17 9.62E-15
immune system development 38 4.98E-17 1.13E-14
cell chemotaxis 40 9.52E-17 2.04E-14
actin cytoskeleton organization 41 1.09E-16 2.28E-14
positive regulation of programmed cell death 42 1.52E-16 3.11E-14
hemopoiesis 43 1.56E-16 3.11E-14
positive regulation of JUN kinase activity 44 1.71E-16 3.33E-14
positive regulation of cell death 45 1.91E-16 3.64E-14
positive regulation of apoptosis 46 2.33E-16 4.34E-14
regulation of intracellular protein kinase cascade 47 4.19E-16 7.65E-14
regulation of mast cell degranulation 48 5.71E-16 1.02E-13
positive regulation of transport 49 7.23E-16 1.27E-13
tissue remodeling 50 8.23E-16 1.41E-13
response to bacterium 51 1.28E-15 2.15E-13
regulation of lymphocyte activation 53 2.20E-15 3.56E-13
positive regulation of angiogenesis 54 2.39E-15 3.81E-13
regulation of JUN kinase activity 60 5.03E-15 7.20E-13
lipid storage 63 8.05E-15 1.10E-12
regulation of I-kappaB kinase/NF-kappaB cascade 64 9.28E-15 1.24E-12
cytoskeleton organization 66 1.55E-14 2.01E-12
inflammatory response 68 2.01E-14 2.53E-12
positive regulation of cell activation 69 2.13E-14 2.64E-12
sequestering of triglyceride 71 2.82E-14 3.41E-12
regulation of intracellular transport 72 3.66E-14 4.36E-12
positive regulation of leukocyte activation 76 6.48E-14 7.32E-12
# Term Name  Binom Rank  Binom Raw P-Value   Binom FDR Q-Value 
regulation of immune system process 2 1.62E-28 6.97E-25
positive regulation of programmed cell death 8 9.26E-22 9.94E-19
positive regulation of cell death 9 6.66E-21 6.35E-18
positive regulation of apoptosis 10 6.75E-21 5.79E-18
regulation of cell activation 17 6.50E-18 3.28E-15
induction of programmed cell death 18 7.24E-18 3.45E-15
ulation of T cell activation 19 1.34E-17 6.04E-15
regulation of leukocyte activation 24 4.42E-17 1.58E-14
induction of apoptosis 26 1.27E-16 4.18E-14
regulation of lymphocyte activation 29 2.69E-16 7.96E-14
actin filament-based process 31 8.51E-15 2.36E-12
response to drug 32 8.84E-15 2.37E-12
negative regulation of immune system process 34 1.17E-14 2.95E-12
r ulation of T cell proliferation 41 1.36E-13 2.85E-11
regulati n of B cell proliferation 45 1.71E-13 3.26E-11
actin cytoskeleton organization 46 2.05E-13 3.82E-11
regulation of B cell activation 58 1.77E-12 2.62E-10
regulation of immune response 59 1.78E-12 2.59E-10
negative regulation of cell migration 63 2.20E-12 3.00E-10
negative regulation of cell activation 65 2.83E-12 3.74E-10
regulation of leukocyte proliferation 67 3.45E-12 4.42E-10
negative regulation of T cell activation 68 3.62E-12 4.56E-10
regulation of mononuclear cell proliferation 69 4. 8E-12 5. 0E-10
regulation of protein serine/threonine kinase activity 73 7.17E-12 8.43E-10
regulation of lymphocyte proliferation 76 8.59E-12 9.71E-10
negative regulation of cell motility 78 1.33E-11 1.46E-09
Ras protein signal transduction 82 1.55E-11 1.63E-09
negative regulation of leukocyte activation 93 6.36E-11 5.87E-09
leukocyte differentiation 94 6.37E-11 5.81E-09
negative regulation of cellular component movement 98 7.47E-11 6.54E-09
endocytosis 99 7.76E-11 6.73E-09
myeloid cell differentiation 107 1.42E-10 1.14E-08
phagocytosis 111 1.64E-10 1.27E-08
regulation of myeloid leukocyte differentiation 112 1.72E-10 1.31E-08
immune response-regulating cell surface receptor signaling pathway 114 1.73E-10 1.30E-08
regulation of angiogenesis 118 2.50E-10 1.82E-08
positive regulation of blood coagulation 119 2.79E-10 2.01E-08
regulation of G1/S transition of mitotic cell cycle 121 3.19E-10 2.27E-08
regulation of endothelial cell differentiation 122 3.27E-10 2.30E-08
regulation of blood coagulation 126 5.40E-10 3.68E-08
regulation of endothelial cell proliferation 129 6.15E-10 4.09E-08
positive regulation of angiogenesis 130 6.36E-10 4.20E-08
immune response-regulating signaling pathway 132 7.38E-10 4.80E-08
negative regulation of T cell proliferation 137 1.07E-09 6.71E-08
positive regulation of coagulation 138 1.13E-09 7.03E-08
regulation of coagulation 140 1.15E-09 7.06E-08
negative regulation of MAP kinase activity 142 1.59E-09 9.60E-08
regulation of body fluid levels 144 1.61E-09 9.60E-08
regulation of MAP kinase activity 147 1.90E-09 1.11E-07
negative regulation of lymphocyte activation 148 1.97E-09 1.14E-07
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Table S 4 
Top 20 “Biological Processes” terms of GREAT analysis on H3K27Ac common ChIPseq peaks 
from low grade HCC samples. 
 
 
 
 
Table S 5 
Top 20 “Biological Processes” terms of GREAT analysis on H3K27Ac common ChIPseq peaks 
from high grade HCC samples. 
 
 
# Term Name  Binom Rank  Binom Raw P-Value   Binom FDR Q-Value
regulation of immune system process 1 8.31E-36 7.13E-32
response to wounding 3 8.48E-26 2.43E-22
wound healing 4 5.43E-25 1.16E-21
actin filament-based process 8 2.40E-20 2.57E-17
positive regulation of angiogenesis 9 2.56E-20 2.44E-17
actin cytoskeleton organization 12 8.25E-20 5.90E-17
negative regulation of immune system process 17 4.77E-18 2.41E-15
regulation of cellular component movement 18 8.34E-18 3.98E-15
regulation of cell migration 19 1.19E-17 5.39E-15
regulation of cell motility 20 1.38E-17 5.94E-15
positive regulation of cell differentiation 21 1.54E-17 6.31E-15
leukocyte chemotaxis 23 2.14E-17 7.99E-15
regulation of angiogenesis 25 2.59E-17 8.90E-15
positive regulation of apoptosis 26 5.91E-17 1.95E-14
regulation of cell activation 27 7.29E-17 2.32E-14
cytoskeleton organization 28 7.72E-17 2.37E-14
positive regulation of programmed cell death 30 8.51E-17 2.44E-14
regulation of leukocyte activation 32 1.48E-16 3.98E-14
cell chemotaxis 33 2.20E-16 5.73E-14
regulation of lymphocyte activation 34 2.74E-16 6.91E-14
positive regulation of cell death 35 3.99E-16 9.79E-14
leukocyte migration 36 1.02E-15 2.44E-13
response to laminar fluid shear stress 38 1.55E-15 3.51E-13
tissue remodeling 39 2.58E-15 5.67E-13
regulation of locomotion 41 3.11E-15 6.52E-13
regulation of T cell activation 42 5.18E-15 1.06E-12
regulation of myeloid cell differentiation 46 1.40E-14 2.62E-12
endocytosis 48 1.65E-14 2.95E-12
negative regulation of cell activation 49 1.83E-14 3.20E-12
induction of apoptosis 55 4.90E-14 7.65E-12
induction of programmed cell death 56 5.81E-14 8.90E-12
positive regulation of cellular component movement 57 6.69E-14 1.01E-11
positive regulation of cell migration 59 2.02E-13 2.94E-11
regulation of protein polymerization 60 2.05E-13 2.93E-11
regulation of response to stress 62 2.27E-13 3.14E-11
positive regulation of cell motility 65 3.54E-13 4.68E-11
negative regulation of leukocyte activation 66 3.75E-13 4.87E-11
regulation of inflammatory response 67 4.14E-13 5.31E-11
regulation of immune response 68 4.44E-13 5.61E-11
regulation of actin polymerization or depolymerization 72 5.83E-13 6.96E-11
response to oxygen levels 73 6.61E-13 7.77E-11
cell activation 74 7.43E-13 8.62E-11
response to fluid shear stress 75 8.52E-13 9.75E-11
regulation of actin filament polymerization 76 9.60E-13 1.08E-10
regulation of actin filament length 77 1.08E-12 1.20E-10
regulation of cytokine production 78 1.38E-12 1.52E-10
regulation of T cell proliferation 79 1.75E-12 1.90E-10
regulation of endothelial cell proliferation 80 1.88E-12 2.02E-10
cellular membrane organization 81 2.20E-12 2.34E-10
membrane organization 82 2.27E-12 2.38E-10
# Term Name  Binom Rank  Binom Raw P-Value   Binom FDR Q-Value  
regulation of immune system process 2 3.09E-30 1.33E-26
response to wounding 9 4.85E-25 4.62E-22
immune response 13 4.44E-22 2.93E-19
actin filament-based process 16 3.20E-20 1.72E-17
actin cytoskeleton organization 18 2.51E-19 1.20E-16
phagocytosis 22 5.29E-18 2.07E-15
regulation of cell activation 25 6.59E-17 2.26E-14
induction of programmed cell death 30 8.26E-16 2.36E-13
regulation of myeloid leukocyte mediated immunity 31 9.39E-16 2.60E-13
ind ction of apoptosis 35 1.69E-15 4.14E- 3
tion of immune response 38 3.00E-15 6.78E- 3
regulation of leukocyte activation 40 5.36E-15 1.15E-12
tissue remodeling 43 5.96E-15 1.19E-12
endocytosis 44 6.66E-15 1.30E-12
regulation of leukocyte degranulation 45 7.91E-15 1.51E-12
leukocyte migration 47 9.48E-15 1.73E-12
regulation of cytokine production 50 1.30E-14 2.24E-12
positive regulation of angiogenesis 55 3.39E-14 5.30E-12
regulation of angiogenesis 56 7.58E-14 1.16E-11
inflammatory response 57 8.73E-14 1.32E-11
wound healing 59 1.38E-13 2.00E-11
response to bacter um 65 5.17E-13 6. 2E-11
leukocyte chemotaxis 69 9.02E-13 1.12E-10
regulation of myeloid cell differentiation 71 1.06E-12 1.28E-10
myeloid cell differentiation 73 1.30E-12 1.53E-10
cell chemotaxis 79 2.18E-12 2.37E-10
regulation of lymphocyte activation 80 2.24E-12 2.40E-10
immune effector process 82 3.00E-12 3.14E-10
regulation of actin polymerization or depolymerization 84 6.49E-12 6.63E-10
regulation of myeloid leukocyte differentiation 88 1.04E-11 1.02E-09
regulation of cellular component size 90 1.15E-11 1.10E-09
regulation of actin filament length 91 1.31E-11 1.24E-09
regulation of actin filament polymerization 93 1.46E-11 1.35E-09
regulation of actin filament-based process 95 2.11E-11 1.91E-09
phagocytosis, engulfment 97 2.41E-11 2.13E-09
response to cadmium ion 99 2.89E-11 2.50E-09
regulation of actin cytoskeleton organization 102 4.52E-11 3.81E-09
regulation of T cell activation 103 4.87E-11 4.06E-09
regulation of body fluid levels 105 6.61E-11 5.40E-09
regulation of mononuclear cell proliferation 107 8.42E-11 6.75E-09
regulation of anatomical structure size 109 9.67E-11 7.62E-09
regulation of lymphocyte proliferation 113 1.59E-10 1.21E-08
regulation of leukocyte proliferation 115 1.71E-10 1.28E-08
response to molecule of bacterial origin 116 1.93E-10 1.43E-08
positive regulation of cell activation 119 2.65E-10 1.91E-08
myeloid leukocyte mediated immunity 120 2.75E-10 1.97E-08
positive regulation of reactive oxygen species metabolic process 123 3.58E-10 2.49E-08
response to lipopolysaccharide 127 4.37E-10 2.95E-08
positive regulation of leukocyte activation 137 8.95E-10 5.61E-08
positive regulation of B cell activation 141 1.16E-09 7.07E-08
 95 
 
Table S 6 
Sequencing settings, throughput and coverage for genomic analyses in Mdr2-KO HCCs. Details 
on the Illumina sequencing are provided, such as the number of samples per lane, the setting 
(PE = paired end sequencing), the mean raw sequenced gigabases (Gbps), and the mean 
coverage of aligned reads in each sample.  
 
 
Lesion ID Sequenced regions
Sequenced 
Mbps
Samples 
per lane
Sequencing 
setting
Raw Gbp 
(mean)
Mean 
coverage
51509/1 126
60400/2 142
218/1 138
52686/1 154
58853/3 146
60400/1 124
58163/3 155
58163/4 105
215/1 159
218/3 11
60400/1 131 101 PE 43.5
22.4
Whole 
exome
50.4 2 101 PE
Whole 
genome
2,600
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Table S 7 
Results of the Map2k7 TaqMan copy number assay on 49 Mdr2-KO nodules. For some nodules, 
histology could not be performed (N.A. = not applicable). WT indicates a normal copy number 
for Map2k7. Nodules that where previously used for WES or WGS are included and indicated. 
Lesion ID Gender Age (months) Size (mm) %carcinoma TaqMan validation Screening
55484/2 F 10 1 N.A. WT -
55484/5 F 10 1 N.A. WT -
54913/3 F 10 2 N.A. Amplified -
54913/4 F 10 1 N.A. WT -
54913/6 F 10 1 N.A. WT -
54913/10 F 10 1 N.A. Amplified -
54913/8 F 10 5 N.A. Amplified -
55481/1 F 10 4 N.A. WT -
55481/4 F 10 3 N.A. WT -
55481/2 F 10 3 N.A. WT -
55481/8 F 10 1 N.A. WT -
55481/9 F 10 3 N.A. WT -
55481/10 F 10 3 N.A. Amplified -
58859/1 F 12 6 N.A. WT -
52682/1 M 11 4 N.A. WT -
52682/2 M 11 5 N.A. WT -
58855/1 M 12 5 N.A. WT -
58855/2 M 12 6 N.A. WT -
55484/1 F 10 3 0 WT -
51505/1 M 14 7 0 WT -
60123/1 M 14 6 0 Amplified -
52687/1 F 15 13 0 WT -
51509/5 M 16 11 0 Amplified -
60400/3 F 13 5 10 WT -
60400/4 F 13 5 10 WT -
58853/1 M 15 15 10 WT -
58853/2 M 15 40 10 WT -
58853/4 M 15 10 10 WT -
58163/1 M 15 40 10 WT -
58163/2 M 15 13 10 WT -
52686/1 F 15 10 20 WT -
52687/2 F 15 9 20 WT -
51509/1 M 16 15 20 WT -
51509/2 M 16 11 20 WT -
51509/3 M 16 8 20 WT -
51509/4 M 16 11 20 WT -
55484/4 F 10 30 30 Amplified -
60400/2 F 13 14 40 Amplified WES
55484/3 F 10 3 50 WT -
218/1 M 15 10 50 WT -
52686/2 F 15 7 50 Amplified WES
60400/1 F 13 9 60 Amplified WES;-WGS
58853/3 M 15 17 60 WT -
218/3 M 15 10 70 Amplified WGS
58163/3 M 15 30 70 Amplified WES
58163/4 M 15 30 70 WT -
51505/2 M 14 N.A. 80 Amplified -
215/1 M 14 18 80 Amplified WES
218/2 M 15 30 90 WT -
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 Normal Degenerative changes
Preneoplastic 
foci Adenoma HCC
79568/1 14 U 11.22 0 50 0 50 0 Amplified
79568/2 14 U NA 0 80 20 0 0 -
79568/4 14 U 2 0 40 20 40 0 -
79568/5 14 U 9.37 0 40 10 50 0 -
81210/1 14 U 22.12 0 30 0 70 0 -
81210/10 14 U 6.8 0 30 0 60 10 -
81210/11 14 U 9 0 20 10 60 10 -
81210/12 14 U NA 0 20 20 60 0 -
81210/2 14 U NA 0 30 30 40 0 -
81210/3 14 U NA 0 40 40 20 0 -
81210/4 14 U NA 0 30 0 70 0 -
81210/5 14 U 10 0 50 10 40 0 -
81210/7 14 U NA 0 70 0 30 0 -
81210/8 14 U 4 0 70 30 0 0 -
81210/9 14 U 7.3 0 0 0 100 0 -
81217/1 14 U 21.87 0 0 0 70 30 -
81217/2 14 U NA 0 70 0 30 0 -
81217/3 14 U NA 0 10 10 80 0 -
81217/4 14 U NA 0 30 10 60 0 -
81217/5 14 U 11.8 0 10 0 90 0 WT
81217/6 14 U 13.6 0 40 1 50 0 WT
81215/1 14 U 6.77 0 0 0 70 30 -
81215/2 14 U 2.9 0 70 10 20 0 -
81215/3 14 U 4.26 0 70 10 20 0 -
81215/4 14 U 4.7 0 10 10 80 0 -
81215/5 14 U 5.5 0 40 30 30 0 -
82367/1 14 U 6.9 0 50 10 30 10 -
82367/2 14 U 3.8 0 50 50 0 0 -
82367/3 14 U NA 0 40 20 30 10 -
82367/5 14 U 2 0 40 40 20 0 -
82367/7 14 U 3.8 0 40 40 20 0 -
82367/8 14 U NA 0 40 20 40 0 -
82367/9 14 U NA 0 30 20 50 0 -
82367/LL 14 U 25.48 0 30 30 30 10 -
81223/1 14 U 10.13 0 20 0 70 10 Amplified
81223/4 14 U 7.58 0 40 10 40 10 -
81223/5 14 U 8.79 0 40 10 40 10 -
81223/6 14 U NA 0 10 10 80 0 -
81223/7 14 U 5 0 10 10 80 0 -
83102/1 13 U 10.6 0 30 20 50 0 WT
83102/2 13 U NA 0 40 20 40 0 -
83102/3 13 U NA 0 60 20 20 0 -
83102/5 13 U 3.9 0 10 10 80 0 -
83102/6 13 U 2.8 0 60 10 30 0 -
83102/LL 13 U 37 0 10 0 40 50 -
83112/1 13 U 11.3 0 0 0 40 60 Amplified
83112/2 13 U NA 0 70 20 10 0 -
83112/3 13 U 2 0 70 30 0 0 -
83112/4 13 U 8.3 0 70 10 20 0 -
83112/5 13 U NA 0 40 0 60 0 -
83112/6 13 U 18.18 0 20 0 60 20 Amplified
87184/1 13 U 10.99 0 30 10 10 50 WT
87184/RL 13 U NA 0 40 10 40 10 -
87183/1 13 U 20.1 0 40 0 50 10 -
87183/2 13 U 10 0 10 0 80 10 -
87183/3 13 U 6.3 0 20 10 70 0 -
87183/5 13 U 11 0 30 10 0 60 WT
87186/1 13 U 2 N.A. N.A. N.A. N.A. N.A. -
88000/1 13 T 18.21 0 20 0 70 10 Amplified
81201/1 14 T 17.16 0 40 0 50 10 WT
81201/5 14 T 8.4 N.A. N.A. N.A. N.A. N.A. -
81203/1 14 T 15.5 0 30 0 70 0 WT
81203/3 14 T 8 0 90 10 0 0 -
81203/4 14 T 2.5 0 30 0 70 0 -
81203/5 14 T 4.3 0 30 0 50 20 -
81203/7 14 T NA 0 40 0 60 0 -
81221/1 14 T 10.53 0 20 0 80 0 WT
81221/2 14 T 3 0 40 10 50 0 -
81221/3 14 T 9 0 20 20 60 0 -
81221/4 14 T 8.2 0 20 10 70 0 -
81221/5 14 T NA 0 50 30 20 0 -
81221/6 14 T NA 0 30 10 60 0 -
81221/7 14 T NA 0 0 0 100 0 -
81221/8 14 T NA 0 100 0 0 0 -
88002/1 13 T 18.35 0 40 0 60 0 WT
88002/3 13 T 6 0 40 0 60 0 -
88002/5 13 T 3.5 0 60 0 40 0 -
82368/1 14 T 8.44 0 0 0 100 0 -
82368/2 14 T NA 0 20 40 40 0 -
82368/3 14 T NA 0 60 10 30 0 -
82368/4 14 T NA 0 40 10 40 10 -
83099/1 13 T 19.4 0 0 0 80 20 WT
83099/2 13 T 7.7 0 0 0 80 20 -
83099/10 13 T NA 0 70 20 10 0 -
83099/11 13 T 4.8 0 40 20 20 20 -
83099/3 13 T 16.5 0 10 0 90 0 WT
83099/4 13 T 16.5 0 10 0 90 0 Insufficient DNA
83099/6 13 T 7.2 0 20 10 40 30 -
83099/7 13 T 8 0 10 20 60 10 -
81214/1 14 T 17.49 0 20 0 80 0 WT
81214/2 14 T 2 0 60 10 30 0 -
81214/3 14 T 10.74 0 40 10 50 0 WT
81214/4 14 T 5.9 0 20 10 70 0 -
81214/5 14 T 5 0 20 40 40 0 -
81214/8 14 T 2 0 20 0 70 10 -
81214/9 14 T 2 0 20 0 70 10 -
81214/11 14 T 2 0 20 0 70 10 -
81214/12 14 T 2 0 20 0 70 10 -
81214/7 14 T 14.58 0 20 10 20 50 Wt
83111/1 13 T NA 0 100 0 0 0 -
83111/2 13 T NA 0 20 40 40 0 -
87187/1 13 T 18.84 0 50 10 30 10 Amplified
87187/2 13 T 6.5 0 30 10 60 0 -
87187/3 13 T 5.9 0 10 0 70 20 -
87187/6 13 T NA 0 80 20 0 0 -
87187/7 13 T NA 0 40 20 40 0 -
87185/1 13 T 9.58 0 50 20 30 0 -
87185/2 13 T 4.5 0 10 0 90 0 -
87185/3 13 T 4.3 0 40 0 50 10 -
87185/4 13 T 6.7 0 20 10 50 20 -
88005/1 13 T 15.25 0 20 10 70 0 Amplified
88005/2 13 T 2.5 0 70 10 20 0 -
TaqMan 
validation
Nodule histological composition (%)
Lesion ID Age (months) Group Size (mm)
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Table S 8 
Description of the nodules isolated after treatment with SP600125 JNK inhibitor. Tumors are 
divided according to groups (T = treated; U = untreated). For each lesion shown are the age of 
the animal at the time of sacrifice, the size in mm of each lesion (for some lesions measurement 
could not be performed, N.A. = not applicable), and the histologic content. TaqMan copy 
number assay was done only on nodules between 10 mm and 20 mm in size to check whether 
the proportion of Map2k7 amplications was comparable in treated and untreated animals, 
results are reported. 
 
 
 
 
 
 
 
 Normal Degenerative changes
Preneoplastic 
foci Adenoma HCC
79568/1 14 U 11.22 0 50 0 50 0 Amplified
79568/2 14 U NA 0 80 20 0 0 -
79568/4 14 U 2 0 40 20 40 0 -
79568/5 14 U 9.37 0 40 10 50 0 -
81210/1 14 U 22.12 0 30 0 70 0 -
81210/10 14 U 6.8 0 30 0 60 10 -
81210/11 14 U 9 0 20 10 60 10 -
81210/12 14 U NA 0 20 20 60 0 -
81210/2 14 U NA 0 30 30 40 0 -
81210/3 14 U NA 0 40 40 20 0 -
81210/4 14 U NA 0 30 0 70 0 -
81210/5 14 U 10 0 50 10 40 0 -
81210/7 14 U NA 0 70 0 30 0 -
81210/8 14 U 4 0 70 30 0 0 -
81210/9 14 U 7.3 0 0 0 100 0 -
81217/1 14 U 21.87 0 0 0 70 30 -
81217/2 14 U NA 0 70 0 30 0 -
81217/3 14 U NA 0 10 10 80 0 -
81217/4 14 U NA 0 30 10 60 0 -
81217/5 14 U 11.8 0 10 0 90 0 WT
81217/6 14 U 13.6 0 40 1 50 0 WT
81215/1 14 U 6.77 0 0 0 70 30 -
81215/2 14 U 2.9 0 70 10 20 0 -
81215/3 14 U 4.26 0 70 10 20 0 -
81215/4 14 U 4.7 0 10 10 80 0 -
81215/5 14 U 5.5 0 40 30 30 0 -
82367/1 14 U 6.9 0 50 10 30 10 -
82367/2 14 U 3.8 0 50 50 0 0 -
82367/3 14 U NA 0 40 20 30 10 -
82367/5 14 U 2 0 40 40 20 0 -
82367/7 14 U 3.8 0 40 40 20 0 -
82367/8 14 U NA 0 40 20 40 0 -
82367/9 14 U NA 0 30 20 50 0 -
82367/LL 14 U 25.48 0 30 30 30 10 -
81223/1 14 U 10.13 0 20 0 70 10 Amplified
81223/4 14 U 7.58 0 40 10 40 10 -
81223/5 14 U 8.79 0 40 10 40 10 -
81223/6 14 U NA 0 10 10 80 0 -
81223/7 14 U 5 0 10 10 80 0 -
83102/1 13 U 10.6 0 30 20 50 0 WT
83102/2 13 U NA 0 40 20 40 0 -
83102/3 13 U NA 0 60 20 20 0 -
83102/5 13 U 3.9 0 10 10 80 0 -
83102/6 13 U 2.8 0 60 10 30 0 -
83102/LL 13 U 37 0 10 0 40 50 -
83112/1 13 U 11.3 0 0 0 40 60 Amplified
83112/2 13 U NA 0 70 20 10 0 -
83112/3 13 U 2 0 70 30 0 0 -
83112/4 13 U 8.3 0 70 10 20 0 -
83112/5 13 U NA 0 40 0 60 0 -
83112/6 13 U 18.18 0 20 0 60 20 Amplified
87184/1 13 U 10.99 0 30 10 10 50 WT
87184/RL 13 U NA 0 40 10 40 10 -
87183/1 13 U 20.1 0 40 0 50 10 -
87183/2 13 U 10 0 10 0 80 10 -
87183/3 13 U 6.3 0 20 10 70 0 -
87183/5 13 U 11 0 30 10 0 60 WT
87186/1 13 U 2 N.A. N.A. N.A. N.A. N.A. -
88000/1 13 T 18.21 0 20 0 70 10 Amplified
81201/1 14 T 17.16 0 40 0 50 10 WT
81201/5 14 T 8.4 N.A. N.A. N.A. N.A. N.A. -
81203/1 14 T 15.5 0 30 0 70 0 WT
81203/3 14 T 8 0 90 10 0 0 -
81203/4 14 T 2.5 0 30 0 70 0 -
81203/5 14 T 4.3 0 30 0 50 20 -
81203/7 14 T NA 0 40 0 60 0 -
81221/1 14 T 10.53 0 20 0 80 0 WT
81221/2 14 T 3 0 40 10 50 0 -
81221/3 14 T 9 0 20 20 60 0 -
81221/4 14 T 8.2 0 20 10 70 0 -
81221/5 14 T NA 0 50 30 20 0 -
81221/6 14 T NA 0 30 10 60 0 -
81221/7 14 T NA 0 0 0 100 0 -
81221/8 14 T NA 0 100 0 0 0 -
88002/1 13 T 18.35 0 40 0 60 0 WT
88002/3 13 T 6 0 40 0 60 0 -
88002/5 13 T 3.5 0 60 0 40 0 -
82368/1 14 T 8.44 0 0 0 100 0 -
82368/2 14 T NA 0 20 40 40 0 -
82368/3 14 T NA 0 60 10 30 0 -
82368/4 14 T NA 0 40 10 40 10 -
83099/1 13 T 19.4 0 0 0 80 20 WT
83099/2 13 T 7.7 0 0 0 80 20 -
83099/10 13 T NA 0 70 20 10 0 -
83099/11 13 T 4.8 0 40 20 20 20 -
83099/3 13 T 16.5 0 10 0 90 0 WT
83099/4 13 T 16.5 0 10 0 90 0 Insufficient DNA
83099/6 13 T 7.2 0 20 10 40 30 -
83099/7 13 T 8 0 10 20 60 10 -
81214/1 14 T 17.49 0 20 0 80 0 WT
81214/2 14 T 2 0 60 10 30 0 -
81214/3 14 T 10.74 0 40 10 50 0 WT
81214/4 14 T 5.9 0 20 10 70 0 -
81214/5 14 T 5 0 20 40 40 0 -
81214/8 14 T 2 0 20 0 70 10 -
81214/9 14 T 2 0 20 0 70 10 -
81214/11 14 T 2 0 20 0 70 10 -
81214/12 14 T 2 0 20 0 70 10 -
81214/7 14 T 14.58 0 20 10 20 50 Wt
83111/1 13 T NA 0 100 0 0 0 -
83111/2 13 T NA 0 20 40 40 0 -
87187/1 13 T 18.84 0 50 10 30 10 Amplified
87187/2 13 T 6.5 0 30 10 60 0 -
87187/3 13 T 5.9 0 10 0 70 20 -
87187/6 13 T NA 0 80 20 0 0 -
87187/7 13 T NA 0 40 20 40 0 -
87185/1 13 T 9.58 0 50 20 30 0 -
87185/2 13 T 4.5 0 10 0 90 0 -
87185/3 13 T 4.3 0 40 0 50 10 -
87185/4 13 T 6.7 0 20 10 50 20 -
88005/1 13 T 15.25 0 20 10 70 0 Amplified
88005/2 13 T 2.5 0 70 10 20 0 -
TaqMan 
validation
Nodule histological composition (%)
Lesion ID Age (months) Group Size (mm)
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Table S 9 
PFIC samples description. For each lesion shown are the conservation of the sample, the 
provenience (BI = Hospital Papa Giovanni XXIII, Bergamo, Italy; LU = King’s College Hospital, 
London, UK; VF = Hôpital Paul Brousse, Villejuif, France; TG = University of Tuebingen, 
Tuebingen, Germany), the histologic evaluation of the matched non-tumoral liver, and the 
percentage of carcinoma content. 
 
 
 
Table S 10 
Sequencing settings, throughput and coverage for genomic analyses in PFIC HCCs. Details on 
the Illumina sequencing are provided, such as the number of samples per lane, the setting (PE 
= paired end sequencing), the sequenced gigabases (Gbps), the Gbps aligned to the genome, 
the Gbps after duplicate removal, the Gbps that were on targeted genomic regions, and the 
mean coverage of aligned reads used for variant calling in each sample. For the matched normal 
of each lesion, we followed the same experimental procedure of the tumor samples. Reported is 
only the mean coverage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lesion ID Age (Years) Gender Conservation Provenience Background liver % carcinoma
175 1.6 M Frozen LU Extensive fibrosis 90%
7860 2.6 F FFPE BI Mild fibrosis 90%
23836 1.3 M FFPE BI Cirrhosis 90%
HB4R 8.6 F Frozen VF Normal liver 70%
1790 11.7 M Frozen LU Mild fibrosis 60%
2896 1.3 F Frozen LU Cirrhosis 50%
MB 1.3 M Frozen TG Cirrhosis 40%
Samples/lane Setting Sequenced Gbps Aligned Gbps Aligned w/o duplicates OnTarget Gbps Mean Coverage
175 2 101 PE 17.15 15.38 11.62 8.17 160 157
7860 1 76 PE 30.3 25.42 3.93 2.57 50 33
23836 2 76 PE 13.46 11.96 8.27 5.52 108 110
HB4R 2 101 PE 16.82 12.27 5.76 2.67 52 150
1790 2 101 PE 8.7 5.99 5.45 4.73 92 146
2896 2 101 PE 9.7 6.46 5.93 5.16 101 239
Tumor
Lesion ID
Mean coverage of 
matched normal
 100 
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